The NYC Memo — Agentic News and Research https://www.nycmemo.com Original, AI-synthesized market briefs from primary sources and long-form research from The NYC Memo. en-us Copyright 2026 The NYC Memo research@nycmemo.com (The NYC Memo Research) research@nycmemo.com (The NYC Memo Research) Fri, 21 Aug 2026 01:31:50 GMT Fri, 21 Aug 2026 00:30:06 GMT 15 https://www.nycmemo.com/og-image.pngThe NYC Memo — Agentic News and Researchhttps://www.nycmemo.com CRWD President and CEO George Kurtz Sold $4.14M of Shares on August 18-19 https://www.nycmemo.com/news/CRWD-President-and-CEO-George-Kurtz-Sold-414M-of-Shares-on-August-18-19?utm_source=newstex&utm_medium=rss nycmemo:wire:cd805384-b6dd-400f-9e7f-63aec7eafd45 Fri, 21 Aug 2026 00:30:06 GMT The NYC Memo insider sale CRWD CrowdStrike Holdings, Inc. President and CEO George Kurtz sold 20,400 shares of common stock for a total of $4,136,215.09 across multiple transactions on August 18 and August 19, 2026. The sales were executed at prices ranging from $198.12 to $214.67 per share and were not made pursuant to a 10b5-1 trading plan. Following these transactions, Mr. Kurtz directly owned 7,926,019 shares of CrowdStrike common stock.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> CrowdStrike Holdings, Inc. President and CEO George Kurtz sold 20,400 shares of common stock for a total of $4,136,215.09 across multiple transactions on August 18 and August 19, 2026. The sales were executed at prices ranging from $198.12 to $214.67 per share and were not made pursuant to a 10b5-1 trading plan. Following these transactions, Mr. Kurtz directly owned 7,926,019 shares of CrowdStrike common stock.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> MU: EVP Sadana Sumit Sells 15,000 Shares for $14.01 Million on August 18 https://www.nycmemo.com/news/MU?utm_source=newstex&utm_medium=rss nycmemo:wire:9cd8047e-c6aa-4dd2-96c8-720f2fe38ee7 Thu, 20 Aug 2026 23:05:21 GMT The NYC Memo insider sale MU Micron Technology (MU) EVP and Chief Business Officer Sadana Sumit disposed of 15,000 shares of common stock at an average price of $934.29 per share on August 18, 2026. The total transaction value for this sale amounted to $14,014,350.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Micron Technology (MU) EVP and Chief Business Officer Sadana Sumit disposed of 15,000 shares of common stock at an average price of $934.29 per share on August 18, 2026. The total transaction value for this sale amounted to $14,014,350.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> META CFO Susan Li Sold 506 Million in Company Stock on August 18 2026 https://www.nycmemo.com/news/META-CFO-Susan-Li-Sold-506-Million-in-Company-Stock-on-August-18-2026?utm_source=newstex&utm_medium=rss nycmemo:wire:8eadcf00-8c69-4191-977d-a515a57b13e3 Thu, 20 Aug 2026 22:33:20 GMT The NYC Memo insider trade META Meta Platforms, Inc. Chief Financial Officer Susan Li disposed of 8,575 shares of META common stock on August 18, 2026. The transactions were executed at prices ranging from $547.51 to $560.63 per share, totaling approximately $5,063,389.

Primary source: SEC Form 4 (META). Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Meta Platforms, Inc. Chief Financial Officer Susan Li disposed of 8,575 shares of META common stock on August 18, 2026. The transactions were executed at prices ranging from $547.51 to $560.63 per share, totaling approximately $5,063,389.

Primary source: SEC Form 4 (META). Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> TPR CEO Joanne Crevoiserat Sold $3.68M Shares, Acquired $1.23M Shares on August 19 https://www.nycmemo.com/news/TPR-CEO-Joanne-Crevoiserat-Sold-368M-Shares-Acquired-123M-Shares-on-August-19?utm_source=newstex&utm_medium=rss nycmemo:wire:013000ab-cd34-40e4-b8ef-5b1bebd65fc8 Thu, 20 Aug 2026 22:26:46 GMT The NYC Memo insider sale TPR TAPESTRY, INC. CEO Joanne C. Crevoiserat reported multiple transactions on August 19, 2026. Crevoiserat sold 27,761 shares of TPR stock for a total value of approximately $3.68 million at an average price of $132.47 per share. She also acquired 66,061 shares through option exercises for approximately $1.23 million.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> TAPESTRY, INC. CEO Joanne C. Crevoiserat reported multiple transactions on August 19, 2026. Crevoiserat sold 27,761 shares of TPR stock for a total value of approximately $3.68 million at an average price of $132.47 per share. She also acquired 66,061 shares through option exercises for approximately $1.23 million.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> CHTR Completes Liberty Broadband Acquisition, $3.5B Cox Deal, Issues 71.1M Shares https://www.nycmemo.com/news/CHTR-Completes-Liberty-Broadband-Acquisition-35B-Cox-Deal-Issues-711M-Shares?utm_source=newstex&utm_medium=rss nycmemo:wire:b2e98662-8e2a-4e4c-a558-46003a1782f9 Thu, 20 Aug 2026 21:16:04 GMT The NYC Memo material agreement CHTR Charter Communications, Inc. (CHTR) completed its acquisition of Liberty Broadband Corporation and a transaction with Cox Enterprises, Inc. on August 19, 2026. In the Liberty transaction, Charter issued approximately 33.9 million shares of Class A Common Stock and 7.2 million shares of Preferred Stock. The Cox transaction involved Charter acquiring Cox's commercial fiber and managed IT businesses for $3.5 billion in cash, with Charter Holdings issuing 60.0 million convertible preferred units ($6.0 billion aggregate liquidation preference) and 33.6 million common units to Cox NewCo.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Charter Communications, Inc. (CHTR) completed its acquisition of Liberty Broadband Corporation and a transaction with Cox Enterprises, Inc. on August 19, 2026. In the Liberty transaction, Charter issued approximately 33.9 million shares of Class A Common Stock and 7.2 million shares of Preferred Stock. The Cox transaction involved Charter acquiring Cox's commercial fiber and managed IT businesses for $3.5 billion in cash, with Charter Holdings issuing 60.0 million convertible preferred units ($6.0 billion aggregate liquidation preference) and 33.6 million common units to Cox NewCo.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> INCY President Pablo Cagnoni Sold 10,801 Shares Worth $1.36M on August 19 https://www.nycmemo.com/news/INCY?utm_source=newstex&utm_medium=rss nycmemo:wire:be4de567-e811-40c6-bed2-bb53c0d02b9c Thu, 20 Aug 2026 21:15:28 GMT The NYC Memo insider sale INCY INCYTE CORP President and Global Head of R&D, Pablo J. Cagnoni, disposed of 10,801 shares of common stock at a price of $125.56 per share on August 19, 2026. This transaction totaled approximately $1,356,173.56, leaving Cagnoni with 183,200 shares directly owned after the sale.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> INCYTE CORP President and Global Head of R&D, Pablo J. Cagnoni, disposed of 10,801 shares of common stock at a price of $125.56 per share on August 19, 2026. This transaction totaled approximately $1,356,173.56, leaving Cagnoni with 183,200 shares directly owned after the sale.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> SYK Director Ronda Stryker Sold $117.78M in Company Stock on August 18-19 https://www.nycmemo.com/news/SYK-Director-Ronda-Stryker-Sold-11778M-in-Company-Stock-on-August-18-19?utm_source=newstex&utm_medium=rss nycmemo:wire:12983f0a-b06d-497e-8739-9f3af36edfd9 Thu, 20 Aug 2026 21:12:27 GMT The NYC Memo insider sale SYK Stryker Corp. Director Ronda Stryker sold a total of 319,258 shares of SYK common stock for a combined value of approximately $117,776,128.25. The sales occurred on August 18 and August 19, 2026, with individual transaction prices ranging from $331.742 to $342.797 per share. These transactions were not executed under a 10b5-1 trading plan.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Stryker Corp. Director Ronda Stryker sold a total of 319,258 shares of SYK common stock for a combined value of approximately $117,776,128.25. The sales occurred on August 18 and August 19, 2026, with individual transaction prices ranging from $331.742 to $342.797 per share. These transactions were not executed under a 10b5-1 trading plan.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> XEL: CPUC Verbally Approved PSCo $157 Million Electric Rate Increase, Reaffirms 2026 EPS Guidance https://www.nycmemo.com/news/XEL?utm_source=newstex&utm_medium=rss nycmemo:wire:7a6ed0e7-d716-432f-8b8a-689cb165cbd5 Thu, 20 Aug 2026 20:58:11 GMT The NYC Memo regulatory action XEL Xcel Energy Inc. reported that on August 19, 2026, the Colorado Public Utilities Commission verbally approved most terms of a non-unanimous settlement for Public Service Company of Colorado's electric rate case. The approved terms include a $157 million (4.4%) revenue increase, a 9.3% Return on Equity, and 54.5% equity ratio. Rates are expected to become effective August 29, 2026, and Xcel Energy reaffirmed its 2026 ongoing earnings per share guidance of $4.04 to $4.16.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Xcel Energy Inc. reported that on August 19, 2026, the Colorado Public Utilities Commission verbally approved most terms of a non-unanimous settlement for Public Service Company of Colorado's electric rate case. The approved terms include a $157 million (4.4%) revenue increase, a 9.3% Return on Equity, and 54.5% equity ratio. Rates are expected to become effective August 29, 2026, and Xcel Energy reaffirmed its 2026 ongoing earnings per share guidance of $4.04 to $4.16.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> HAL Director Jeffrey Slocum Sold 52,572 Shares Worth $1.84 Million on August 19 https://www.nycmemo.com/news/HAL-Director-Jeffrey-Slocum-Sold-52572-Shares-Worth-184-Million-on-August-19?utm_source=newstex&utm_medium=rss nycmemo:wire:8170fc1d-b9d8-43b6-b2be-46d89dbb917f Thu, 20 Aug 2026 20:52:42 GMT The NYC Memo insider sale HAL HALLIBURTON CO Director, EVP and COO Jeffrey Shannon Slocum disposed of 52,572 shares of common stock on August 19, 2026. The shares were sold at a price of $35.09 each, totaling $1,844,751.48. Following the transaction, Slocum directly owns 118,729.952 shares.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> HALLIBURTON CO Director, EVP and COO Jeffrey Shannon Slocum disposed of 52,572 shares of common stock on August 19, 2026. The shares were sold at a price of $35.09 each, totaling $1,844,751.48. Following the transaction, Slocum directly owns 118,729.952 shares.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> RSG: Cascade Investment Purchased $83.4 Million of Republic Services Stock https://www.nycmemo.com/news/RSG-4?utm_source=newstex&utm_medium=rss nycmemo:wire:541a3128-ceff-40be-a73b-56e9e406f36c Thu, 20 Aug 2026 20:36:59 GMT The NYC Memo insider purchase RSG Cascade Investment, L.L.C., a more than 10% owner of Republic Services, Inc., purchased 378,610 shares of common stock for a total of $83,402,937.35. The transactions occurred on August 18 and August 19, 2026, at prices ranging from $216.65 to $224.09 per share.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Cascade Investment, L.L.C., a more than 10% owner of Republic Services, Inc., purchased 378,610 shares of common stock for a total of $83,402,937.35. The transactions occurred on August 18 and August 19, 2026, at prices ranging from $216.65 to $224.09 per share.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> DVN Appoints Three EVPs, Including CTO Kevin Smith; Two Officers Depart by September 1 https://www.nycmemo.com/news/DVN-Appoints-Three-EVPs-Including-CTO-Kevin-Smith-Two-Officers-Depart-by?utm_source=newstex&utm_medium=rss nycmemo:wire:c0808a16-4154-4b60-94b6-4feb5830d432 Thu, 20 Aug 2026 20:34:19 GMT The NYC Memo executive change DVN Devon Energy Corporation announced executive leadership changes effective August 20, 2026. Tom Hellman and Robert (Trey) Lowe III were appointed Executive Vice Presidents, Exploration & Production, and Kevin Smith was named Executive Vice President and Chief Technology Officer. John Raines and Michael DeShazer are departing the company as of September 1, 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Devon Energy Corporation announced executive leadership changes effective August 20, 2026. Tom Hellman and Robert (Trey) Lowe III were appointed Executive Vice Presidents, Exploration & Production, and Kevin Smith was named Executive Vice President and Chief Technology Officer. John Raines and Michael DeShazer are departing the company as of September 1, 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> ABT: Abbott Settles 'Gill' Lawsuit, 2,000 NEC Claims for $670 Million on August 20, 2026 https://www.nycmemo.com/news/ABT?utm_source=newstex&utm_medium=rss nycmemo:wire:e6e39c76-f2f5-493a-ac87-a2d3f4e167b8 Thu, 20 Aug 2026 20:33:15 GMT The NYC Memo regulatory action ABT Abbott (ABT) entered into agreements on August 20, 2026, to resolve the 'Gill' lawsuit and approximately 2,000 necrotizing enterocolitis (NEC) claims for an aggregate amount of approximately $670 million. This settlement follows a Missouri state court verdict in July 2024 of $495 million in damages, affirmed in May 2026, and estimated at $600 million including accrued interest. The company stated these agreements are a compromise of disputed claims, not an admission of liability, aiming to substantially resolve the overall litigation.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Abbott (ABT) entered into agreements on August 20, 2026, to resolve the 'Gill' lawsuit and approximately 2,000 necrotizing enterocolitis (NEC) claims for an aggregate amount of approximately $670 million. This settlement follows a Missouri state court verdict in July 2024 of $495 million in damages, affirmed in May 2026, and estimated at $600 million including accrued interest. The company stated these agreements are a compromise of disputed claims, not an admission of liability, aiming to substantially resolve the overall litigation.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> ECL: CEO Beck Sold $5.00M in Ecolab Shares on August 18, 2026 https://www.nycmemo.com/news/ECL?utm_source=newstex&utm_medium=rss nycmemo:wire:bb6eb089-a373-4396-a230-6c29f16f2822 Thu, 20 Aug 2026 20:33:01 GMT The NYC Memo insider sale ECL Ecolab Inc. (ECL) Chairman, President & CEO Christophe Beck disposed of 17,862 shares of common stock at an average price of $280.138 per share on August 18, 2026. This transaction totaled approximately $5,003,825 and was not executed under a 10b5-1 trading plan. Following the sale, Beck directly holds 72,932.118 shares of Ecolab common stock.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Ecolab Inc. (ECL) Chairman, President & CEO Christophe Beck disposed of 17,862 shares of common stock at an average price of $280.138 per share on August 18, 2026. This transaction totaled approximately $5,003,825 and was not executed under a 10b5-1 trading plan. Following the sale, Beck directly holds 72,932.118 shares of Ecolab common stock.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> CTVA Subsidiary Amends EIDP Note Indenture, Eliminating Restrictive Covenants and Defaults https://www.nycmemo.com/news/CTVA-Subsidiary-Amends-EIDP-Note-Indenture-Eliminating-Restrictive-Covenants?utm_source=newstex&utm_medium=rss nycmemo:wire:c134fa07-7d7b-4a72-aa0f-4debe9bb1b77 Thu, 20 Aug 2026 20:32:47 GMT The NYC Memo material agreement CTVA Corteva, Inc.'s subsidiary Vylor Inc. received Requisite Consents and Majority Consents as of August 19, 2026, for its consent solicitations. EIDP, Inc. subsequently entered a Fourth Supplemental Indenture on August 20, 2026, with U.S. Bank Trust Company, National Association, to amend the EIDP Base Indenture and Supplemental Indentures, eliminating substantially all restrictive covenants, events of default (except payment and bankruptcy-related), and change of control repurchase provisions for 2.300% Senior Notes due 2030, 5.125% Senior Notes due 2032, and 4.800% Senior Notes due 2033.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Corteva, Inc.'s subsidiary Vylor Inc. received Requisite Consents and Majority Consents as of August 19, 2026, for its consent solicitations. EIDP, Inc. subsequently entered a Fourth Supplemental Indenture on August 20, 2026, with U.S. Bank Trust Company, National Association, to amend the EIDP Base Indenture and Supplemental Indentures, eliminating substantially all restrictive covenants, events of default (except payment and bankruptcy-related), and change of control repurchase provisions for 2.300% Senior Notes due 2030, 5.125% Senior Notes due 2032, and 4.800% Senior Notes due 2033.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> RCL Completes $1.25B Offering of 5.550% Senior Notes Due 2034; Net Proceeds $1.24B https://www.nycmemo.com/news/RCL-Completes-125B-Offering-of-5550-Senior-Notes-Due-2034-Net-Proceeds-124B?utm_source=newstex&utm_medium=rss nycmemo:wire:1d4599f7-e19b-4c76-910f-7f8e66dd8cb4 Thu, 20 Aug 2026 20:30:45 GMT The NYC Memo material agreement RCL Royal Caribbean Cruises Ltd. (RCL) completed an offering of $1,250,000,000 aggregate principal amount of its 5.550% Senior Notes due 2034 on August 20, 2026. The company received net proceeds of approximately $1.24 billion, which it intends to use to repay a portion of outstanding borrowings under existing debt facilities. Interest will accrue at 5.550% per annum, payable semi-annually beginning January 20, 2027, with maturity on January 20, 2034.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Royal Caribbean Cruises Ltd. (RCL) completed an offering of $1,250,000,000 aggregate principal amount of its 5.550% Senior Notes due 2034 on August 20, 2026. The company received net proceeds of approximately $1.24 billion, which it intends to use to repay a portion of outstanding borrowings under existing debt facilities. Interest will accrue at 5.550% per annum, payable semi-annually beginning January 20, 2027, with maturity on January 20, 2034.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> AMD Chair and CEO Lisa Su Sold 721M Shares on August 18 2026 https://www.nycmemo.com/news/AMD-Chair-and-CEO-Lisa-Su-Sold-721M-Shares-on-August-18-2026?utm_source=newstex&utm_medium=rss nycmemo:wire:19aa3cea-efb5-4bcb-bd71-0177e3aac9f2 Thu, 20 Aug 2026 20:25:53 GMT The NYC Memo insider trade AMD ADVANCED MICRO DEVICES INC Chair, President & CEO Lisa T Su sold 15,200 shares of common stock on August 18, 2026. The sales were executed at prices ranging from $475.90 to $490.36 per share, totaling $7,214,067.34. Following these transactions, Ms. Su directly held 3,102,656 shares.

Primary source: SEC Form 4 (AMD). Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> ADVANCED MICRO DEVICES INC Chair, President & CEO Lisa T Su sold 15,200 shares of common stock on August 18, 2026. The sales were executed at prices ranging from $475.90 to $490.36 per share, totaling $7,214,067.34. Following these transactions, Ms. Su directly held 3,102,656 shares.

Primary source: SEC Form 4 (AMD). Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> ICE Completed $3.71 Billion Senior Notes Offering to Fund MarketAxess Acquisition https://www.nycmemo.com/news/ICE-Completed-371-Billion-Senior-Notes-Offering-to-Fund-MarketAxess-Acquisition?utm_source=newstex&utm_medium=rss nycmemo:wire:7da549e6-425a-475e-af2d-f2fba43a9e82 Thu, 20 Aug 2026 20:22:57 GMT The NYC Memo material agreement ICE MKTX Intercontinental Exchange, Inc. (ICE) completed a public offering of $3.71 billion in senior notes on August 20, 2026. The offering included $1.25 billion of 4.700% notes due 2029, $1.1 billion of 4.900% notes due 2031, $650 million of 5.150% notes due 2033, and $750 million of 5.400% notes due 2036. ICE stated these net proceeds will fund the acquisition of MarketAxess Holdings Inc., announced on July 30, 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Intercontinental Exchange, Inc. (ICE) completed a public offering of $3.71 billion in senior notes on August 20, 2026. The offering included $1.25 billion of 4.700% notes due 2029, $1.1 billion of 4.900% notes due 2031, $650 million of 5.150% notes due 2033, and $750 million of 5.400% notes due 2036. ICE stated these net proceeds will fund the acquisition of MarketAxess Holdings Inc., announced on July 30, 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> NEM Appoints Peter David Beaven as Independent Director, Audit Committee Member, Effective Sep 1, 2026 https://www.nycmemo.com/news/NEM-Appoints-Peter-David-Beaven-as-Independent-Director-Audit-Committee-Member?utm_source=newstex&utm_medium=rss nycmemo:wire:26bd6b08-ac27-45a2-9cbf-9189a9804cb2 Thu, 20 Aug 2026 20:17:00 GMT The NYC Memo executive change NEM Newmont Corporation's Board of Directors appointed Peter David Beaven, age 59, as an independent director, effective September 1, 2026. Mr. Beaven will also serve on the Audit Committee of the Board from the same date. He previously served as Group Chief Financial Officer of BHP from 2015 to 2021.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Newmont Corporation's Board of Directors appointed Peter David Beaven, age 59, as an independent director, effective September 1, 2026. Mr. Beaven will also serve on the Audit Committee of the Board from the same date. He previously served as Group Chief Financial Officer of BHP from 2015 to 2021.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> RL Chief Operating Officer Robert Ranftl Sold $1.096M Stock on August 18 https://www.nycmemo.com/news/RL-Chief-Operating-Officer-Robert-Ranftl-Sold-1096M-Stock-on-August-18?utm_source=newstex&utm_medium=rss nycmemo:wire:481210a7-7599-4736-a2a2-77f8aa9e44fd Thu, 20 Aug 2026 20:15:21 GMT The NYC Memo insider sale RL RL Chief Operating Officer Robert P. Ranftl disposed of 2,901 shares of common stock at a price of $377.8116 per share on August 18, 2026. The transaction totaled $1,096,031.45 and left Ranftl with 7,261 shares remaining.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> RL Chief Operating Officer Robert P. Ranftl disposed of 2,901 shares of common stock at a price of $377.8116 per share on August 18, 2026. The transaction totaled $1,096,031.45 and left Ranftl with 7,261 shares remaining.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> ROST Reports Q2 2026 Revenue $6.3B, EPS $2.66; Raises FY26 EPS Guidance to $8.61-$8.77 https://www.nycmemo.com/news/ROST-Reports-Q2-2026-Revenue-63B-EPS-266-Raises-FY26-EPS-Guidance-to-861-877?utm_source=newstex&utm_medium=rss nycmemo:wire:be4c3de5-66fc-42d0-94ea-624cafc8090b Thu, 20 Aug 2026 20:11:01 GMT The NYC Memo earnings announcement ROST Ross Stores, Inc. announced Q2 2026 financial results, reporting revenue of $6.3 billion, a 13% year-over-year increase, and GAAP EPS of $2.66. The company also raised its fiscal year 2026 EPS projections to a range of $8.61 to $8.77, which includes a $0.60 benefit from IEEPA tariff refunds.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Ross Stores, Inc. announced Q2 2026 financial results, reporting revenue of $6.3 billion, a 13% year-over-year increase, and GAAP EPS of $2.66. The company also raised its fiscal year 2026 EPS projections to a range of $8.61 to $8.77, which includes a $0.60 benefit from IEEPA tariff refunds.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> COHR CFO Sherri R. Luther Sold 3,000 Shares for $972,000 on August 18, 2026 https://www.nycmemo.com/news/COHR-CFO-Sherri-R-Luther-Sold-3000-Shares-for-972000-on-August-18-2026?utm_source=newstex&utm_medium=rss nycmemo:wire:671bed3d-c05b-4ef2-8494-545fb9b62b35 Thu, 20 Aug 2026 20:07:57 GMT The NYC Memo insider sale COHR Coherent Corp. CFO Sherri R. Luther sold 3,000 shares of COHR common stock on August 18, 2026, at a price of $324 per share. The total transaction value for the sale amounted to $972,000, leaving Luther with 64,475 shares owned after the transaction.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Coherent Corp. CFO Sherri R. Luther sold 3,000 shares of COHR common stock on August 18, 2026, at a price of $324 per share. The total transaction value for the sale amounted to $972,000, leaving Luther with 64,475 shares owned after the transaction.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> VEEV Appoints Dan Rizzo EVP, Sales, Consulting, and Services; Thomas Schwenger Resigns https://www.nycmemo.com/news/VEEV-Appoints-Dan-Rizzo-EVP-Sales-Consulting-and-Services-Thomas-Schwenger?utm_source=newstex&utm_medium=rss nycmemo:wire:b14812c1-9211-4c88-8453-3aa7bcd14793 Thu, 20 Aug 2026 20:05:25 GMT The NYC Memo executive change VEEV Veeva Systems Inc. announced the appointment of Dan Rizzo as Executive Vice President, Sales, Consulting, and Services, effective October 2, 2026. Mr. Rizzo succeeds Thomas D. Schwenger, who resigned from the position on August 18, 2026, with his departure also effective October 2, 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Veeva Systems Inc. announced the appointment of Dan Rizzo as Executive Vice President, Sales, Consulting, and Services, effective October 2, 2026. Mr. Rizzo succeeds Thomas D. Schwenger, who resigned from the position on August 18, 2026, with his departure also effective October 2, 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> TMO Sr. VP Lisa Britt Sold $7.01M Thermo Fisher Shares After Option Exercise on August 19 https://www.nycmemo.com/news/TMO-Sr-VP-Lisa-Britt-Sold-701M-Thermo-Fisher-Shares-After-Option-Exercise-on?utm_source=newstex&utm_medium=rss nycmemo:wire:29d115c8-a820-45f0-a780-7afe9859c751 Thu, 20 Aug 2026 20:02:02 GMT The NYC Memo insider sale TMO Lisa P. Britt, Thermo Fisher Scientific Inc.'s Sr. VP and Chief HR Officer, disposed of 11,440 TMO shares for $7,014,092.80 on August 19, 2026, at a price of $613.12 per share. This followed the acquisition of 11,440 shares on the same day through option exercise at $418.32 per share.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Lisa P. Britt, Thermo Fisher Scientific Inc.'s Sr. VP and Chief HR Officer, disposed of 11,440 TMO shares for $7,014,092.80 on August 19, 2026, at a price of $613.12 per share. This followed the acquisition of 11,440 shares on the same day through option exercise at $418.32 per share.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> AMAT Reports Q3 2026 Revenue $9,115M, EPS $3.17; Revenue up 25% https://www.nycmemo.com/news/AMAT-Reports-Q3-2026-Revenue-9115M-EPS-317-Revenue-up-25?utm_source=newstex&utm_medium=rss nycmemo:wire:d72ffa48-a46a-47af-b334-ea30a2359185 Thu, 20 Aug 2026 20:01:46 GMT The NYC Memo financial results AMAT Applied Materials, Inc. (AMAT) reported Q3 2026 revenue of $9,115 million, a 25% year-over-year increase, with diluted EPS rising to $3.17 from $2.22 in the prior year period. The company recorded a $253 million legal settlement charge in the first nine months of fiscal 2026 related to a previously disclosed export controls compliance matter, and noted ongoing risks from global trade issues and changes in export regulations, particularly affecting China-bound products.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Applied Materials, Inc. (AMAT) reported Q3 2026 revenue of $9,115 million, a 25% year-over-year increase, with diluted EPS rising to $3.17 from $2.22 in the prior year period. The company recorded a $253 million legal settlement charge in the first nine months of fiscal 2026 related to a previously disclosed export controls compliance matter, and noted ongoing risks from global trade issues and changes in export regulations, particularly affecting China-bound products.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Federal Reserve Board announces approval of application by National Westminster Bank Plc https://www.nycmemo.com/news/Federal-Reserve-Board-announces-approval-of-application-by-National-Westminster?utm_source=newstex&utm_medium=rss nycmemo:wire:c621b6f2-ca06-4b1d-aa2a-a1dfcbd80982 Thu, 20 Aug 2026 20:00:00 GMT The NYC Memo Markets The Federal Reserve Board approved an application filed by National Westminster Bank Plc, granting the UK-based lender regulatory clearance for its proposed U.S. activity. Specific terms of the application — whether a branch, acquisition, or holding company action — were not disclosed in the release. NatWest (NWG) is the primary ticker of interest; no domestic U.S. bank counterparty has been identified.

Primary source: Federal Reserve. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The Federal Reserve Board approved an application filed by National Westminster Bank Plc, granting the UK-based lender regulatory clearance for its proposed U.S. activity. Specific terms of the application — whether a branch, acquisition, or holding company action — were not disclosed in the release. NatWest (NWG) is the primary ticker of interest; no domestic U.S. bank counterparty has been identified.

Primary source: Federal Reserve. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Federal Reserve Board issues enforcement actions with former employee of Regions Bank and former employee of United Community Bank https://www.nycmemo.com/news/Federal-Reserve-Board-issues-enforcement-actions-with-former-employee-of-2?utm_source=newstex&utm_medium=rss nycmemo:wire:ae6e6329-e763-48aa-8b25-242d5385bac6 Thu, 20 Aug 2026 15:00:00 GMT The NYC Memo Markets The Federal Reserve Board issued enforcement actions against a former employee of Regions Bank and a former employee of United Community Bank, citing unspecified individual misconduct. These actions target former personnel rather than the institutions themselves, limiting direct regulatory exposure for either bank. RF and UCB shareholders face no immediate institutional liability, though compliance scrutiny of mid-tier regional banks remains an ongoing backdrop.

Primary source: Federal Reserve. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The Federal Reserve Board issued enforcement actions against a former employee of Regions Bank and a former employee of United Community Bank, citing unspecified individual misconduct. These actions target former personnel rather than the institutions themselves, limiting direct regulatory exposure for either bank. RF and UCB shareholders face no immediate institutional liability, though compliance scrutiny of mid-tier regional banks remains an ongoing backdrop.

Primary source: Federal Reserve. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Federal Reserve Board issues enforcement action with SouthPoint Bancshares, Inc. and announces termination of enforcement action with Deutsche Bank AG, DB USA Corporation, and Deutsche Bank AG New York Branch https://www.nycmemo.com/news/Federal-Reserve-Board-issues-enforcement-action-with-SouthPoint-Bancshares-Inc?utm_source=newstex&utm_medium=rss nycmemo:wire:59e500c8-5e7f-491b-be53-ad849aebee03 Thu, 20 Aug 2026 15:00:00 GMT The NYC Memo Markets The Federal Reserve issued a fresh enforcement action against SouthPoint Bancshares, Inc. while simultaneously terminating its existing enforcement action against Deutsche Bank AG, DB USA Corporation, and Deutsche Bank AG New York Branch. The Deutsche Bank termination signals regulators are satisfied with remediation efforts at the German lender's U.S. operations. DB is the primary publicly traded name to watch on the termination news; SouthPoint Bancshares is a private entity with no listed ticker.

Primary source: Federal Reserve. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The Federal Reserve issued a fresh enforcement action against SouthPoint Bancshares, Inc. while simultaneously terminating its existing enforcement action against Deutsche Bank AG, DB USA Corporation, and Deutsche Bank AG New York Branch. The Deutsche Bank termination signals regulators are satisfied with remediation efforts at the German lender's U.S. operations. DB is the primary publicly traded name to watch on the termination news; SouthPoint Bancshares is a private entity with no listed ticker.

Primary source: Federal Reserve. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Sysco Adds Jason Murray and Thomas Ondrof to Board, Effective September 1 https://www.nycmemo.com/news/Sysco-Adds-Jason-Murray-and-Thomas-Ondrof-to-Board-Effective-September-1?utm_source=newstex&utm_medium=rss nycmemo:wire:ae0c708e-2f07-490f-b009-6066ed2b97fb Thu, 20 Aug 2026 12:04:55 GMT The NYC Memo executive change SYY Sysco's Board of Directors voted on August 14, 2026 to expand from eleven to thirteen members and elected Jason Murray, co-founder and CEO of Shipium Corp., and Thomas Ondrof, former EVP and CFO of Aramark Corporation, to fill the new seats effective September 1, 2026. Murray was appointed to the Technology Committee, which was simultaneously renamed the Artificial Intelligence Transformation & Technology Committee, while Ondrof joined the Audit Committee. The accompanying press release reiterated fiscal 2027 guidance of 6%–7% revenue growth and 9%–11% adjusted EPS growth, a $100 million AI-enabled cost-savings program, and the pending acquisition of Jetro Restaurant Depot.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Sysco's Board of Directors voted on August 14, 2026 to expand from eleven to thirteen members and elected Jason Murray, co-founder and CEO of Shipium Corp., and Thomas Ondrof, former EVP and CFO of Aramark Corporation, to fill the new seats effective September 1, 2026. Murray was appointed to the Technology Committee, which was simultaneously renamed the Artificial Intelligence Transformation & Technology Committee, while Ondrof joined the Audit Committee. The accompanying press release reiterated fiscal 2027 guidance of 6%–7% revenue growth and 9%–11% adjusted EPS growth, a $100 million AI-enabled cost-savings program, and the pending acquisition of Jetro Restaurant Depot.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> CTVA Subsidiary Vylor Receives 86-94% Early Tender in $1.6B EIDP Note Exchange https://www.nycmemo.com/news/CTVA-Subsidiary-Vylor-Receives-86-94-Early-Tender-in-16B-EIDP-Note-Exchange?utm_source=newstex&utm_medium=rss nycmemo:wire:fa2ca730-665d-4a90-ac4f-0903ed5e1c0f Thu, 20 Aug 2026 12:00:17 GMT The NYC Memo restructuring CTVA Corteva's wholly owned subsidiary Vylor Inc. disclosed early tender results as of August 19, 2026, showing $431.6M (86.33%) of 2.300% Senior Notes due 2030, $468.4M (93.69%) of 5.125% Senior Notes due 2032, and $524.9M (87.48%) of 4.800% Senior Notes due 2033 validly tendered in exchange offers swapping EIDP, Inc. senior notes for corresponding Vylor notes. Requisite Consents and Majority Consents for proposed amendments — which would eliminate substantially all restrictive covenants and change-of-control repurchase provisions from EIDP's indentures — were received. The exchange offer expiration date was extended from September 3, 2026 to September 29, 2026, with settlement targeted on or about October 1, 2026, concurrent with Corteva's planned separation into two independent publicly traded companies.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Corteva's wholly owned subsidiary Vylor Inc. disclosed early tender results as of August 19, 2026, showing $431.6M (86.33%) of 2.300% Senior Notes due 2030, $468.4M (93.69%) of 5.125% Senior Notes due 2032, and $524.9M (87.48%) of 4.800% Senior Notes due 2033 validly tendered in exchange offers swapping EIDP, Inc. senior notes for corresponding Vylor notes. Requisite Consents and Majority Consents for proposed amendments — which would eliminate substantially all restrictive covenants and change-of-control repurchase provisions from EIDP's indentures — were received. The exchange offer expiration date was extended from September 3, 2026 to September 29, 2026, with settlement targeted on or about October 1, 2026, concurrent with Corteva's planned separation into two independent publicly traded companies.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Allstate Estimates $682M Pre-Tax Catastrophe Losses From 23 July 2026 Events https://www.nycmemo.com/news/Allstate-Estimates-682M-Pre-Tax-Catastrophe-Losses-From-23-July-2026-Events?utm_source=newstex&utm_medium=rss nycmemo:wire:eabd7f04-b802-4f06-9cc8-4d7e7b7fc636 Thu, 20 Aug 2026 11:45:23 GMT The NYC Memo financial results ALL Allstate disclosed estimated catastrophe losses of $682 million pre-tax ($539 million after-tax) for July 2026, spanning 23 separate events. Approximately 75% of the total losses were attributable to two wind and hail events. The figures were disclosed in a press release dated August 20, 2026, signed by Senior Vice President and Chief Accounting Officer Eric K. Ferren, and are estimates subject to change.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Allstate disclosed estimated catastrophe losses of $682 million pre-tax ($539 million after-tax) for July 2026, spanning 23 separate events. Approximately 75% of the total losses were attributable to two wind and hail events. The figures were disclosed in a press release dated August 20, 2026, signed by Senior Vice President and Chief Accounting Officer Eric K. Ferren, and are estimates subject to change.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> CAH CEO Jason Hollar Sells $29.4M of Cardinal Health Stock Over Two Days https://www.nycmemo.com/news/CAH-CEO-Jason-Hollar-Sells-294M-of-Cardinal-Health-Stock-Over-Two-Days?utm_source=newstex&utm_medium=rss nycmemo:wire:5fa9a186-ff3f-4265-a513-8269dc65259e Thu, 20 Aug 2026 11:33:33 GMT The NYC Memo insider sale CAH Cardinal Health CEO Jason Hollar sold 124,529 shares of CAH across ten transactions on August 18–19, 2026, at prices ranging from $233.22 to $237.88 per share, for total proceeds of approximately $29.4 million. None of the sales were executed under a pre-arranged 10b5-1 trading plan. Following the transactions, Hollar retained approximately 190,603 shares of Cardinal Health common stock.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Cardinal Health CEO Jason Hollar sold 124,529 shares of CAH across ten transactions on August 18–19, 2026, at prices ranging from $233.22 to $237.88 per share, for total proceeds of approximately $29.4 million. None of the sales were executed under a pre-arranged 10b5-1 trading plan. Following the transactions, Hollar retained approximately 190,603 shares of Cardinal Health common stock.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> CAH GMPD Segment CEO Stephen Mason Sells $8.3M of Cardinal Health Stock https://www.nycmemo.com/news/CAH-GMPD-Segment-CEO-Stephen-Mason-Sells-83M-of-Cardinal-Health-Stock?utm_source=newstex&utm_medium=rss nycmemo:wire:ad1c40b2-536d-49d5-a5d6-e785ceb1d2e9 Thu, 20 Aug 2026 11:30:36 GMT The NYC Memo insider sale CAH Stephen M. Mason, CEO of Cardinal Health's GMPD Segment, sold 35,000 shares of CAH common stock on August 18, 2026, across four transactions at prices ranging from $234.59 to $237.26 per share, totaling approximately $8.27 million. None of the transactions were conducted under a Rule 10b5-1 plan. Following the sales, Mason held 18,061 shares of CAH.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Stephen M. Mason, CEO of Cardinal Health's GMPD Segment, sold 35,000 shares of CAH common stock on August 18, 2026, across four transactions at prices ranging from $234.59 to $237.26 per share, totaling approximately $8.27 million. None of the transactions were conducted under a Rule 10b5-1 plan. Following the sales, Mason held 18,061 shares of CAH.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> CAH CFO Aaron Alt Sells $9.9M of Cardinal Health Stock on August 18 https://www.nycmemo.com/news/CAH-CFO-Aaron-Alt-Sells-99M-of-Cardinal-Health-Stock-on-August-18?utm_source=newstex&utm_medium=rss nycmemo:wire:4f61d085-ff25-4d2c-bb2e-549f65291c29 Thu, 20 Aug 2026 11:29:44 GMT The NYC Memo insider sale CAH Cardinal Health CFO Aaron Alt sold 42,000 shares of CAH across four tranches on August 18, 2026, at prices ranging from $234.55 to $237.26 per share, for total proceeds of approximately $9.93 million. None of the transactions were executed under a 10b5-1 plan. Alt retained 20,495 shares following the sales.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Cardinal Health CFO Aaron Alt sold 42,000 shares of CAH across four tranches on August 18, 2026, at prices ranging from $234.55 to $237.26 per share, for total proceeds of approximately $9.93 million. None of the transactions were executed under a 10b5-1 plan. Alt retained 20,495 shares following the sales.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> DE Reports Q3 2026 Net Income $1.379B, $5.10 EPS; Sales Rise 5% to $12.608B https://www.nycmemo.com/news/DE-Reports-Q3-2026-Net-Income-1379B-510-EPS-Sales-Rise-5-to-12608B?utm_source=newstex&utm_medium=rss nycmemo:wire:2c1402a4-e810-45eb-bee1-4748e07db81e Thu, 20 Aug 2026 10:00:40 GMT The NYC Memo earnings announcement DE Deere & Company (DE) announced Q3 2026 financial results on August 20, 2026, reporting net income of $1.379 billion, or $5.10 per share. This increased from $1.289 billion, or $4.75 per share, in the prior year period. Worldwide net sales and revenues for the quarter rose 5% to $12.608 billion.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Deere & Company (DE) announced Q3 2026 financial results on August 20, 2026, reporting net income of $1.379 billion, or $5.10 per share. This increased from $1.289 billion, or $4.75 per share, in the prior year period. Worldwide net sales and revenues for the quarter rose 5% to $12.608 billion.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Truth Social: James Braid, our Director of Legislative Affairs, will be leaving the White House in September. https://www.nycmemo.com/news/Truth-Social-386?utm_source=newstex&utm_medium=rss nycmemo:wire:3c81e5ed-7678-4d0e-8bee-1cbd437ed6a4 Thu, 20 Aug 2026 09:40:00 GMT The NYC Memo presidential statement The President announced the September departure of White House Director of Legislative Affairs James Braid, citing past legislative accomplishments; no policy changes, regulatory actions, or market-moving directives were announced.

Primary source: Truth Social. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The President announced the September departure of White House Director of Legislative Affairs James Braid, citing past legislative accomplishments; no policy changes, regulatory actions, or market-moving directives were announced.

Primary source: Truth Social. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Class 2 Device Recall Esteem Body Soft Convex Urostomy Pouch - accessdata.fda.gov https://www.nycmemo.com/news/Class-2-Device-Recall-Esteem-Body-Soft-Convex-Urostomy-Pouch-accessdatafdagov?utm_source=newstex&utm_medium=rss nycmemo:wire:09c6acea-815b-4e61-9fa8-c931c3419102 Thu, 20 Aug 2026 09:37:57 GMT The NYC Memo Markets The FDA classified a Class 2 recall on the Esteem Body Soft Convex Urostomy Pouch, indicating the product presents a risk of temporary or medically reversible adverse health consequences. Class 2 recalls carry moderate regulatory weight but rarely trigger significant commercial disruption for diversified medical device manufacturers. No publicly traded ticker has been identified as the sponsor; traders should monitor FDA accessdata filings for the responsible party to assess supply chain or liability exposure.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA classified a Class 2 recall on the Esteem Body Soft Convex Urostomy Pouch, indicating the product presents a risk of temporary or medically reversible adverse health consequences. Class 2 recalls carry moderate regulatory weight but rarely trigger significant commercial disruption for diversified medical device manufacturers. No publicly traded ticker has been identified as the sponsor; traders should monitor FDA accessdata filings for the responsible party to assess supply chain or liability exposure.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Class 1 Device Recall BMC/REACTHEALTH Luna G3 APAP (LG 3600) - accessdata.fda.gov https://www.nycmemo.com/news/Class-1-Device-Recall-BMCREACTHEALTH-Luna-G3-APAP-LG-3600-accessdatafdagov?utm_source=newstex&utm_medium=rss nycmemo:wire:0a9d251e-e419-46d6-bb37-8930feebd41b Thu, 20 Aug 2026 09:37:57 GMT The NYC Memo Markets The FDA has classified the BMC/ReActHealth Luna G3 APAP (Model LG 3600) auto-adjusting positive airway pressure device under a Class 1 recall, the agency's most serious category, indicating use of the device carries a reasonable probability of serious adverse health consequences or death. ReActHealth is a privately held sleep therapy company with no publicly traded ticker, limiting direct equity exposure. Traders should monitor publicly traded CPAP/sleep device competitors including Philips (PHG) and ResMed (RMD) for any secondary demand shift or regulatory contagion risk.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA has classified the BMC/ReActHealth Luna G3 APAP (Model LG 3600) auto-adjusting positive airway pressure device under a Class 1 recall, the agency's most serious category, indicating use of the device carries a reasonable probability of serious adverse health consequences or death. ReActHealth is a privately held sleep therapy company with no publicly traded ticker, limiting direct equity exposure. Traders should monitor publicly traded CPAP/sleep device competitors including Philips (PHG) and ResMed (RMD) for any secondary demand shift or regulatory contagion risk.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Class 2 Device Recall Veritas Standard Reverse Total Shoulder - accessdata.fda.gov https://www.nycmemo.com/news/Class-2-Device-Recall-Veritas-Standard-Reverse-Total-Shoulder-accessdatafdagov?utm_source=newstex&utm_medium=rss nycmemo:wire:ba469bbc-5513-4da4-98f0-04be3ec2f809 Thu, 20 Aug 2026 07:29:03 GMT The NYC Memo Markets The FDA has classified a recall of the Veritas Standard Reverse Total Shoulder implant system as Class 2, indicating the device presents a risk of temporary or medically reversible adverse health consequences. Class 2 recalls require immediate corrective action but fall below the threshold of life-threatening risk. Integra LifeSciences (IART) is the primary ticker to watch; orthopedic device peers including Zimmer Biomet (ZBH) and Stryker (SYK) face no direct exposure.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA has classified a recall of the Veritas Standard Reverse Total Shoulder implant system as Class 2, indicating the device presents a risk of temporary or medically reversible adverse health consequences. Class 2 recalls require immediate corrective action but fall below the threshold of life-threatening risk. Integra LifeSciences (IART) is the primary ticker to watch; orthopedic device peers including Zimmer Biomet (ZBH) and Stryker (SYK) face no direct exposure.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Power Morcellation During Gynecologic Laparoscopic Surgeries - fda.gov https://www.nycmemo.com/news/Power-Morcellation-During-Gynecologic-Laparoscopic-Surgeries-fdagov?utm_source=newstex&utm_medium=rss nycmemo:wire:65a1eba2-bea7-4e44-9f5f-cb7a777ff331 Thu, 20 Aug 2026 05:05:00 GMT The NYC Memo Markets The FDA has updated its safety communication on power morcellation during gynecologic laparoscopic procedures, reinforcing restrictions on use due to the risk of spreading undetected uterine cancer. The agency's boxed warning, first issued in 2014, limits morcellator use to specific contained systems for women with fibroids. Surgical device makers including J&J's Ethicon unit (JNJ) and Olympus (OLYMP) face continued commercial headwinds in this product category; no new enforcement action or market withdrawal is indicated at this stage.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA has updated its safety communication on power morcellation during gynecologic laparoscopic procedures, reinforcing restrictions on use due to the risk of spreading undetected uterine cancer. The agency's boxed warning, first issued in 2014, limits morcellator use to specific contained systems for women with fibroids. Surgical device makers including J&J's Ethicon unit (JNJ) and Olympus (OLYMP) face continued commercial headwinds in this product category; no new enforcement action or market withdrawal is indicated at this stage.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> VMRK EVP Edward Schulman Sold 16,595 Shares for $1.07 Million https://www.nycmemo.com/news/VMRK-EVP-Edward-Schulman-Sold-16595-Shares-for-107-Million?utm_source=newstex&utm_medium=rss nycmemo:wire:5fd024c1-0293-45c7-a2d5-685cb925fa61 Thu, 20 Aug 2026 01:15:14 GMT The NYC Memo insider sale VMRK VIVMARK RESIDENTIAL EVP, Legal Affairs Edward M. Schulman disposed of 16,595 company shares on August 18, 2026. The transaction was executed at a price of $64.29 per share, totaling $1,066,892.55.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> VIVMARK RESIDENTIAL EVP, Legal Affairs Edward M. Schulman disposed of 16,595 company shares on August 18, 2026. The transaction was executed at a price of $64.29 per share, totaling $1,066,892.55.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Genglycos (pariglasgene brecaparvovec-opnr) FDA Approval History - Drugs.com https://www.nycmemo.com/news/Genglycos-pariglasgene-brecaparvovec-opnr-FDA-Approval-History-Drugscom?utm_source=newstex&utm_medium=rss nycmemo:wire:6ded9f62-9b90-4e13-b999-50d9e7f75bf6 Thu, 20 Aug 2026 01:11:31 GMT The NYC Memo Markets The FDA has approved Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy developed by Ultragenyx Pharmaceutical targeting glycogen storage disease type Ia (GSD Ia). GSD Ia is a rare metabolic disorder with a limited treatment landscape, positioning Genglycos as a potential first-in-class gene therapy for a high-unmet-need orphan indication. Watch RARE as the primary beneficiary; competitors in the rare metabolic and gene therapy space including CRSP, BLUE, and AVRO face incremental competitive pressure in the orphan gene therapy market.

Primary source: Drugs.com Approvals. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA has approved Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy developed by Ultragenyx Pharmaceutical targeting glycogen storage disease type Ia (GSD Ia). GSD Ia is a rare metabolic disorder with a limited treatment landscape, positioning Genglycos as a potential first-in-class gene therapy for a high-unmet-need orphan indication. Watch RARE as the primary beneficiary; competitors in the rare metabolic and gene therapy space including CRSP, BLUE, and AVRO face incremental competitive pressure in the orphan gene therapy market.

Primary source: Drugs.com Approvals. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> VMRK Executive VP & COO Michael L. Manelis Sold $503,225 Shares on August 17, 2026 https://www.nycmemo.com/news/VMRK-Executive-VP-COO-Michael-L-Manelis-Sold-503225-Shares-on-August-17-2026?utm_source=newstex&utm_medium=rss nycmemo:wire:caf1a2ec-7eef-4f13-a2a9-879911c160f7 Thu, 20 Aug 2026 00:58:41 GMT The NYC Memo insider sale VMRK VIVMARK RESIDENTIAL Executive Vice President & COO Michael L. Manelis disposed of 7,825 shares of common stock at a price of $64.31 per share on August 17, 2026. The total value of the transaction was $503,225.75, leaving him with 44,713 shares owned after the reported sale.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> VIVMARK RESIDENTIAL Executive Vice President & COO Michael L. Manelis disposed of 7,825 shares of common stock at a price of $64.31 per share on August 17, 2026. The total value of the transaction was $503,225.75, leaving him with 44,713 shares owned after the reported sale.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> EQR Director Charles E. Mueller Jr. Sold 8,000 Shares for $511,200 https://www.nycmemo.com/news/EQR-Director-Charles-E-Mueller-Jr-Sold-8000-Shares-for-511200?utm_source=newstex&utm_medium=rss nycmemo:wire:7c2a836d-3b0f-4f01-9f7a-027832359334 Thu, 20 Aug 2026 00:42:55 GMT The NYC Memo insider sale EQR VMRK EQR (VIVMARK RESIDENTIAL) Director Charles E. Mueller Jr. sold 8,000 shares of common stock on August 18, 2026, at a price of $63.90 per share. The transaction totaled $511,200, leaving Mr. Mueller Jr. with 16,084 shares directly owned.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> EQR (VIVMARK RESIDENTIAL) Director Charles E. Mueller Jr. sold 8,000 shares of common stock on August 18, 2026, at a price of $63.90 per share. The transaction totaled $511,200, leaving Mr. Mueller Jr. with 16,084 shares directly owned.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> TKO CFO Andrew M. Schleimer Sold 9,942 Shares for $1.93 Million on August 18 https://www.nycmemo.com/news/TKO-CFO-Andrew-M-Schleimer-Sold-9942-Shares-for-193-Million-on-August-18?utm_source=newstex&utm_medium=rss nycmemo:wire:b7590447-4da2-4f8e-80c7-05f5512c2d46 Thu, 20 Aug 2026 00:30:08 GMT The NYC Memo insider sale TKO TKO Group Holdings, Inc. Chief Financial Officer Andrew M. Schleimer sold 9,942 shares of common stock at a price of $194.39 per share on August 18, 2026. This transaction followed the acquisition of 17,753 shares through option exercise on August 17, 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> TKO Group Holdings, Inc. Chief Financial Officer Andrew M. Schleimer sold 9,942 shares of common stock at a price of $194.39 per share on August 18, 2026. This transaction followed the acquisition of 17,753 shares through option exercise on August 17, 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> TKO CEO Ariel Emanuel Sold 24,702 Shares for $4.8 Million on August 18 https://www.nycmemo.com/news/TKO-CEO-Ariel-Emanuel-Sold-24702-Shares-for-48-Million-on-August-18?utm_source=newstex&utm_medium=rss nycmemo:wire:ab42175f-d696-4a9d-bfca-317618b3f679 Thu, 20 Aug 2026 00:30:06 GMT The NYC Memo insider sale TKO TKO Group Holdings, Inc. Chief Executive Officer Ariel Emanuel sold 24,702 shares of common stock at an average price of $194.39 per share on August 18, 2026. This transaction totaled approximately $4,801,822. Emanuel now directly owns 174,334 shares of TKO common stock.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> TKO Group Holdings, Inc. Chief Executive Officer Ariel Emanuel sold 24,702 shares of common stock at an average price of $194.39 per share on August 18, 2026. This transaction totaled approximately $4,801,822. Emanuel now directly owns 174,334 shares of TKO common stock.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> TKO Officer Mark S. Shapiro Sold $3.72M Shares on August 18, 2026 https://www.nycmemo.com/news/TKO-Officer-Mark-S-Shapiro-Sold-372M-Shares-on-August-18-2026?utm_source=newstex&utm_medium=rss nycmemo:wire:08b83563-7536-4cb1-869d-55ceeaca0614 Thu, 20 Aug 2026 00:30:05 GMT The NYC Memo insider sale TKO TKO Group Holdings, Inc. officer and director Mark S. Shapiro disposed of 19,120 shares of common stock at a price of $194.39 per share on August 18, 2026. This transaction resulted in a total sale value of $3,716,736.80.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> TKO Group Holdings, Inc. officer and director Mark S. Shapiro disposed of 19,120 shares of common stock at a price of $194.39 per share on August 18, 2026. This transaction resulted in a total sale value of $3,716,736.80.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> FDA Grants Accelerated Approval for Genglycos - Drugs.com https://www.nycmemo.com/news/FDA-Grants-Accelerated-Approval-for-Genglycos-Drugscom?utm_source=newstex&utm_medium=rss nycmemo:wire:b6c92207-1281-4f41-b2f9-7da913f672e6 Thu, 20 Aug 2026 00:20:40 GMT The NYC Memo Markets The FDA awarded accelerated approval to Genglycos, a drug whose sponsor and full indication details require confirmation from the primary filing. Accelerated approval designations typically signal unmet medical need in rare or serious conditions, with post-marketing confirmatory trials required to maintain approval status. No ticker is yet confirmed; traders should cross-reference the NDA/BLA sponsor to identify the beneficiary equity.

Primary source: Drugs.com Approvals. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA awarded accelerated approval to Genglycos, a drug whose sponsor and full indication details require confirmation from the primary filing. Accelerated approval designations typically signal unmet medical need in rare or serious conditions, with post-marketing confirmatory trials required to maintain approval status. No ticker is yet confirmed; traders should cross-reference the NDA/BLA sponsor to identify the beneficiary equity.

Primary source: Drugs.com Approvals. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> FDA Weighs in on the Development and Use of Digitally Derived Measures for Clinical Investigations - fda.gov https://www.nycmemo.com/news/FDA-Weighs-in-on-the-Development-and-Use-of-Digitally-Derived-Measures-for?utm_source=newstex&utm_medium=rss nycmemo:wire:1bb85a27-b802-4dd2-8886-73b4fb03e2fd Thu, 20 Aug 2026 00:00:00 GMT The NYC Memo Markets The FDA published guidance outlining standards for the development and use of digitally derived measures—data collected via wearables, sensors, and digital health tools—in clinical investigations. The framework establishes validation and qualification expectations for sponsors integrating digital endpoints into trial design. Companies with digital health and clinical-stage assets—including Medidata (DDOG parent Veeva VEEV), Apple AAPL, and wearable-adjacent CROs like ICLR and CRL—face updated regulatory parameters for trial submissions.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA published guidance outlining standards for the development and use of digitally derived measures—data collected via wearables, sensors, and digital health tools—in clinical investigations. The framework establishes validation and qualification expectations for sponsors integrating digital endpoints into trial design. Companies with digital health and clinical-stage assets—including Medidata (DDOG parent Veeva VEEV), Apple AAPL, and wearable-adjacent CROs like ICLR and CRL—face updated regulatory parameters for trial submissions.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Key Considerations for the Development and Use of Digitally Derived Measures for Clinical Investigations, FDA Paper - fda.gov https://www.nycmemo.com/news/Key-Considerations-for-the-Development-and-Use-of-Digitally-Derived-Measures?utm_source=newstex&utm_medium=rss nycmemo:wire:b4d016c5-6019-46c2-878a-17243342c139 Thu, 20 Aug 2026 00:00:00 GMT The NYC Memo Markets The FDA released a guidance document outlining key considerations for the development and use of digitally derived measures—data collected via wearables, sensors, and digital health tools—in clinical trials. The paper establishes a framework for sponsors seeking to integrate digital endpoints into drug and device development programs. No specific company or product is named; broad implications touch digital health platform developers and CROs including Veeva Systems (VEEV), Medidata parent Dassault Systèmes (DASTY), and wearable-adjacent names like Apple (AAPL) and Garmin (GRMN).

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA released a guidance document outlining key considerations for the development and use of digitally derived measures—data collected via wearables, sensors, and digital health tools—in clinical trials. The paper establishes a framework for sponsors seeking to integrate digital endpoints into drug and device development programs. No specific company or product is named; broad implications touch digital health platform developers and CROs including Veeva Systems (VEEV), Medidata parent Dassault Systèmes (DASTY), and wearable-adjacent names like Apple (AAPL) and Garmin (GRMN).

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Medline Removes Bupivacaine Hydrochloride from Convenience Kits - fda.gov https://www.nycmemo.com/news/Medline-Removes-Bupivacaine-Hydrochloride-from-Convenience-Kits-fdagov?utm_source=newstex&utm_medium=rss nycmemo:wire:edaed4a2-3675-4d95-b9a3-993da430ad26 Thu, 20 Aug 2026 00:00:00 GMT The NYC Memo Markets Medline Industries has initiated a voluntary recall removing bupivacaine hydrochloride, a local anesthetic, from its pre-assembled surgical convenience kits, per an FDA recall notice dated August 20, 2026. The scope and lot details of the affected kits have not been publicly disclosed in the raw filing. Medline is privately held, limiting direct equity impact; hospital supply chain operators and competing anesthetic kit distributors such as Becton Dickinson (BD) warrant monitoring for any downstream procurement shifts.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Medline Industries has initiated a voluntary recall removing bupivacaine hydrochloride, a local anesthetic, from its pre-assembled surgical convenience kits, per an FDA recall notice dated August 20, 2026. The scope and lot details of the affected kits have not been publicly disclosed in the raw filing. Medline is privately held, limiting direct equity impact; hospital supply chain operators and competing anesthetic kit distributors such as Becton Dickinson (BD) warrant monitoring for any downstream procurement shifts.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome - Drugs.com https://www.nycmemo.com/news/US-FDA-Accepts-Tevas-New-Drug-Application-NDA-and-Grants-Priority-Review-for?utm_source=newstex&utm_medium=rss nycmemo:wire:9e3dc955-8b62-45e3-a448-5a7f4e73891d Wed, 19 Aug 2026 22:41:00 GMT The NYC Memo fda action The FDA accepted Teva Pharmaceutical's New Drug Application for ecopipam, a first-in-class D1/D5 dopamine receptor antagonist, and granted Priority Review designation for the treatment of Tourette Syndrome in pediatric patients. Priority Review designation accelerates the FDA's review timeline to six months versus the standard ten, signaling a potential approval decision in early-to-mid 2027. TEVA is the primary beneficiary; no approved competitors exist in this specific pediatric Tourette indication, giving ecopipam potential first-mover exclusivity in an underserved market.

Primary source: Drugs.com Approvals. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA accepted Teva Pharmaceutical's New Drug Application for ecopipam, a first-in-class D1/D5 dopamine receptor antagonist, and granted Priority Review designation for the treatment of Tourette Syndrome in pediatric patients. Priority Review designation accelerates the FDA's review timeline to six months versus the standard ten, signaling a potential approval decision in early-to-mid 2027. TEVA is the primary beneficiary; no approved competitors exist in this specific pediatric Tourette indication, giving ecopipam potential first-mover exclusivity in an underserved market.

Primary source: Drugs.com Approvals. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Pasatru (garetosmab-grts) FDA Approval History - Drugs.com https://www.nycmemo.com/news/Pasatru-garetosmab-grts-FDA-Approval-History-Drugscom?utm_source=newstex&utm_medium=rss nycmemo:wire:1f0301f8-e048-4462-9284-ed291df1b6a6 Wed, 19 Aug 2026 22:25:44 GMT The NYC Memo Markets The FDA has approved Pasatru (garetosmab-grts), Regeneron's monoclonal antibody targeting activin A, for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder causing progressive heterotopic ossification. FOP affects an estimated 800 patients in the U.S., positioning Pasatru as a high-price orphan drug with limited but captive market potential. REGN is the primary beneficiary; watch for analyst peak-sales estimates and any label breadth commentary at launch.

Primary source: Drugs.com Approvals. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA has approved Pasatru (garetosmab-grts), Regeneron's monoclonal antibody targeting activin A, for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder causing progressive heterotopic ossification. FOP affects an estimated 800 patients in the U.S., positioning Pasatru as a high-price orphan drug with limited but captive market potential. REGN is the primary beneficiary; watch for analyst peak-sales estimates and any label breadth commentary at launch.

Primary source: Drugs.com Approvals. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> FDA Approves Pasatru (garetosmab-grts) for the Treatment of Fibrodysplasia Ossificans Progressiva - Drugs.com https://www.nycmemo.com/news/FDA-Approves-Pasatru-garetosmab-grts-for-the-Treatment-of-Fibrodysplasia?utm_source=newstex&utm_medium=rss nycmemo:wire:72d06eba-0544-4148-9cbd-f9fc903f38d3 Wed, 19 Aug 2026 21:55:30 GMT The NYC Memo Markets The FDA granted approval to Pasatru (garetosmab-grts), developed by Regeneron Pharmaceuticals, for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder causing soft tissue to ossify progressively. FOP affects an estimated 800 patients in the U.S., making this a niche but significant rare-disease franchise win for Regeneron. REGN is the primary beneficiary; watch for analyst updates on orphan-drug revenue contribution and potential pricing disclosures in coming days.

Primary source: Drugs.com Approvals. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA granted approval to Pasatru (garetosmab-grts), developed by Regeneron Pharmaceuticals, for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder causing soft tissue to ossify progressively. FOP affects an estimated 800 patients in the U.S., making this a niche but significant rare-disease franchise win for Regeneron. REGN is the primary beneficiary; watch for analyst updates on orphan-drug revenue contribution and potential pricing disclosures in coming days.

Primary source: Drugs.com Approvals. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> XYZ Director Eisen Anthony Mathew Sold $1.44M in Company Stock Over Three Days https://www.nycmemo.com/news/XYZ-Director-Eisen-Anthony-Mathew-Sold-144M-in-Company-Stock-Over-Three-Days?utm_source=newstex&utm_medium=rss nycmemo:wire:0d12af14-06ee-4e7b-82b0-d87acfe7f0f6 Wed, 19 Aug 2026 21:42:55 GMT The NYC Memo insider sale XYZ XYZ Director Eisen Anthony Mathew sold 18,000 shares of common stock for a total of $1,442,100. The sales occurred across three transactions between August 17 and August 19, 2026, at average prices ranging from $79.17 to $81.63 per share. These sales were not executed under a 10b5-1 trading plan.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> XYZ Director Eisen Anthony Mathew sold 18,000 shares of common stock for a total of $1,442,100. The sales occurred across three transactions between August 17 and August 19, 2026, at average prices ranging from $79.17 to $81.63 per share. These sales were not executed under a 10b5-1 trading plan.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> B. Braun Medical Inc. Issues Voluntary North American Recall of Excel® Lactated Ringers Injection, 1000mL Due to the Presence of Particulate Matter - fda.gov https://www.nycmemo.com/news/B-Braun-Medical-Inc-Issues-Voluntary-North-American-Recall-of-Excel-Lactated-2?utm_source=newstex&utm_medium=rss nycmemo:wire:215b296e-db97-4ce3-8aa0-75d7a6f9f082 Wed, 19 Aug 2026 21:36:00 GMT The NYC Memo Markets B. Braun Medical Inc. has initiated a voluntary North American recall of its Excel Lactated Ringers Injection (1000mL) due to the presence of particulate matter, which poses a risk of adverse patient outcomes including vascular occlusion or inflammation. The recall covers a widely used IV fluid product administered in hospital and clinical settings. B. Braun is privately held, limiting direct equity impact, but competing IV fluid suppliers such as Baxter International (BAX) and ICU Medical (ICUI) stand to benefit from supply displacement in the near term.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> B. Braun Medical Inc. has initiated a voluntary North American recall of its Excel Lactated Ringers Injection (1000mL) due to the presence of particulate matter, which poses a risk of adverse patient outcomes including vascular occlusion or inflammation. The recall covers a widely used IV fluid product administered in hospital and clinical settings. B. Braun is privately held, limiting direct equity impact, but competing IV fluid suppliers such as Baxter International (BAX) and ICU Medical (ICUI) stand to benefit from supply displacement in the near term.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia https://www.nycmemo.com/news/FDA-Approves-First-Therapy-for-Patients-aged-8-years-and-older-with-Glycogen?utm_source=newstex&utm_medium=rss nycmemo:wire:e21f1a7e-64d9-4711-8963-6967b15c95dd Wed, 19 Aug 2026 21:33:10 GMT The NYC Memo Markets The FDA approved the first treatment indicated for glycogen storage disease type Ia (GSD Ia) in patients aged 8 years and older, marking a landmark regulatory milestone for a rare metabolic disorder with no prior approved therapy. GSD Ia affects an estimated 1 in 100,000 births, representing a small but high-unmet-need orphan population that typically commands premium pricing and strong reimbursement. No sponsor company or ticker was identified in the raw filing; traders should monitor orphan drug-focused biotechs and confirm the sponsoring entity via the FDA press announcement for direct equity exposure.

Primary source: FDA. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA approved the first treatment indicated for glycogen storage disease type Ia (GSD Ia) in patients aged 8 years and older, marking a landmark regulatory milestone for a rare metabolic disorder with no prior approved therapy. GSD Ia affects an estimated 1 in 100,000 births, representing a small but high-unmet-need orphan population that typically commands premium pricing and strong reimbursement. No sponsor company or ticker was identified in the raw filing; traders should monitor orphan drug-focused biotechs and confirm the sponsoring entity via the FDA press announcement for direct equity exposure.

Primary source: FDA. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> CVX President Andrew Walz Sold $3.38M Shares After Acquiring $2.05M Options on August 17 https://www.nycmemo.com/news/CVX-President-Andrew-Walz-Sold-338M-Shares-After-Acquiring-205M-Options-on?utm_source=newstex&utm_medium=rss nycmemo:wire:d3179df4-dfa2-4790-8d89-ef8fba63453c Wed, 19 Aug 2026 21:23:03 GMT The NYC Memo insider sale CVX Chevron Corporation's President of Downstream & Chemicals, Andrew Benjamin Walz, acquired 16,800 shares through option exercises for $2.05 million on August 17, 2026. On the same day, Walz sold 16,800 shares of common stock for a total transaction value of $3,377,833.20, leaving him with 14 shares directly owned.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Chevron Corporation's President of Downstream & Chemicals, Andrew Benjamin Walz, acquired 16,800 shares through option exercises for $2.05 million on August 17, 2026. On the same day, Walz sold 16,800 shares of common stock for a total transaction value of $3,377,833.20, leaving him with 14 shares directly owned.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> B. Braun Medical Inc. Issues Voluntary North American Recall of Excel® Lactated Ringers Injection, 1000mL Due to the Presence of Particulate Matter https://www.nycmemo.com/news/B-Braun-Medical-Inc-Issues-Voluntary-North-American-Recall-of-Excel-Lactated?utm_source=newstex&utm_medium=rss nycmemo:wire:d98f951b-b83b-4b70-b494-ea2c550e77d4 Wed, 19 Aug 2026 21:07:00 GMT The NYC Memo Markets B. Braun Medical Inc. has initiated a voluntary North American recall of its Excel Lactated Ringers Injection (1000mL) after particulate matter was detected in the IV solution. The recall affects a widely used hospital-setting crystalloid fluid, raising supply and liability concerns for the privately held German medical device company. B. Braun is not publicly traded; hospital system operators and competing IV fluid suppliers — including Baxter International (BAX) and ICU Medical (ICUI) — stand to absorb displaced demand.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> B. Braun Medical Inc. has initiated a voluntary North American recall of its Excel Lactated Ringers Injection (1000mL) after particulate matter was detected in the IV solution. The recall affects a widely used hospital-setting crystalloid fluid, raising supply and liability concerns for the privately held German medical device company. B. Braun is not publicly traded; hospital system operators and competing IV fluid suppliers — including Baxter International (BAX) and ICU Medical (ICUI) — stand to absorb displaced demand.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> SHW President Justin T Binns Sold $4.76M of Stock on August 17 https://www.nycmemo.com/news/SHW-President-Justin-T-Binns-Sold-476M-of-Stock-on-August-17?utm_source=newstex&utm_medium=rss nycmemo:wire:f376c90d-3c7f-4657-b4a7-8f9793d6e00f Wed, 19 Aug 2026 21:01:55 GMT The NYC Memo insider sale SHW Justin T Binns, President, Glob. Architectural at Sherwin-Williams Company (SHW), disposed of 13,500 shares of common stock at a price of $352.70 per share on August 17, 2026. This transaction resulted in a total sale value of $4,761,450.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Justin T Binns, President, Glob. Architectural at Sherwin-Williams Company (SHW), disposed of 13,500 shares of common stock at a price of $352.70 per share on August 17, 2026. This transaction resulted in a total sale value of $4,761,450.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> RTX EVP Maharajh Ramsaran Sold $4.49M Company Stock, Exercised $1.44M Options on August 18 https://www.nycmemo.com/news/RTX-EVP-Maharajh-Ramsaran-Sold-449M-Company-Stock-Exercised-144M-Options-on?utm_source=newstex&utm_medium=rss nycmemo:wire:84dbe948-85aa-404d-a5fa-8a5c1f9f2d4d Wed, 19 Aug 2026 20:56:55 GMT The NYC Memo insider sale RTX RTX Executive Vice President and General Counsel Maharajh Ramsaran disposed of 6,414 shares for $1,437,184.98 and sold 13,655 shares for $3,057,563.42 on August 18, 2026. These transactions followed the acquisition of 20,069 shares via option exercise at $71.62 per share, totaling $1,437,341.78, on the same date.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> RTX Executive Vice President and General Counsel Maharajh Ramsaran disposed of 6,414 shares for $1,437,184.98 and sold 13,655 shares for $3,057,563.42 on August 18, 2026. These transactions followed the acquisition of 20,069 shares via option exercise at $71.62 per share, totaling $1,437,341.78, on the same date.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> SNA Chairman, President, CEO Pinchuk Sold $14.84M Stock on August 18 https://www.nycmemo.com/news/SNA-Chairman-President-CEO-Pinchuk-Sold-1484M-Stock-on-August-18?utm_source=newstex&utm_medium=rss nycmemo:wire:3d1a8181-61d3-46c8-abb1-94419dd267b8 Wed, 19 Aug 2026 20:56:53 GMT The NYC Memo insider sale SNA Nicholas T. Pinchuk, Chairman, President, and CEO of SNA, disposed of 27,289 shares of common stock on August 18, 2026. The sales were executed across multiple transactions at prices ranging from $397.50 to $401.93 per share, totaling approximately $14,842,134. Pinchuk acquired 33,750 shares through an option exercise at $168.70 per share on the same date.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Nicholas T. Pinchuk, Chairman, President, and CEO of SNA, disposed of 27,289 shares of common stock on August 18, 2026. The sales were executed across multiple transactions at prices ranging from $397.50 to $401.93 per share, totaling approximately $14,842,134. Pinchuk acquired 33,750 shares through an option exercise at $168.70 per share on the same date.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> CNC Secretary & General Counsel Koster Sold 47,603 Shares for $3.11M on August 18 https://www.nycmemo.com/news/CNC-Secretary-General-Counsel-Koster-Sold-47603-Shares-for-311M-on-August-18?utm_source=newstex&utm_medium=rss nycmemo:wire:bbe12dc5-b4ff-473a-a444-3a4aa3cb2ac6 Wed, 19 Aug 2026 20:45:23 GMT The NYC Memo insider sale CNC CNC Secretary & General Counsel Christopher Koster disposed of 47,603 common shares at a price of $65.36 per share on August 18, 2026. The transaction totaled $3,111,332.08 and was not executed under a 10b5-1 trading plan.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> CNC Secretary & General Counsel Christopher Koster disposed of 47,603 common shares at a price of $65.36 per share on August 18, 2026. The transaction totaled $3,111,332.08 and was not executed under a 10b5-1 trading plan.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Prince Bakery Inc Issues Allergy Alert on Undeclared Milk and Sesame in Prince Bakery Breads - fda.gov https://www.nycmemo.com/news/Prince-Bakery-Inc-Issues-Allergy-Alert-on-Undeclared-Milk-and-Sesame-in-Prince-2?utm_source=newstex&utm_medium=rss nycmemo:wire:5b3f7b9f-eda2-4b87-b873-d958c7d2540f Wed, 19 Aug 2026 20:43:39 GMT The NYC Memo Markets Prince Bakery Inc has issued a voluntary allergy alert for its bread products after undeclared milk and sesame were identified as unlabeled ingredients, triggering an FDA recall action. The affected products pose a risk to consumers with dairy or sesame allergies. Prince Bakery is a private company; no publicly traded tickers are directly implicated in this action.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Prince Bakery Inc has issued a voluntary allergy alert for its bread products after undeclared milk and sesame were identified as unlabeled ingredients, triggering an FDA recall action. The affected products pose a risk to consumers with dairy or sesame allergies. Prince Bakery is a private company; no publicly traded tickers are directly implicated in this action.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> HOOD CFO Shiv Verma Sold 3,982 Shares for $378,568 on August 17 https://www.nycmemo.com/news/HOOD-CFO-Shiv-Verma-Sold-3982-Shares-for-378568-on-August-17?utm_source=newstex&utm_medium=rss nycmemo:wire:af84bbd5-a53d-4893-b3cb-ed3334d14387 Wed, 19 Aug 2026 20:42:47 GMT The NYC Memo insider sale HOOD Robinhood Markets, Inc. CFO Shiv Verma disposed of 3,982 common shares at a weighted average price of $95.07 per share on August 17, 2026. The total transaction value for this sale amounted to $378,568.74, leaving Verma Shiv with 51,963 shares directly owned.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Robinhood Markets, Inc. CFO Shiv Verma disposed of 3,982 common shares at a weighted average price of $95.07 per share on August 17, 2026. The total transaction value for this sale amounted to $378,568.74, leaving Verma Shiv with 51,963 shares directly owned.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> ARE Executive Chairman Joel Marcus Purchased 5,000 Shares for $231,400 https://www.nycmemo.com/news/ARE-Executive-Chairman-Joel-Marcus-Purchased-5000-Shares-for-231400?utm_source=newstex&utm_medium=rss nycmemo:wire:2fbaa159-0e1f-421c-9b0d-e7ab250c62db Wed, 19 Aug 2026 20:37:12 GMT The NYC Memo insider purchase ARE ARE Executive Chairman Joel S. Marcus acquired 5,000 shares of common stock through an open market purchase on August 17, 2026. The transaction totaled $231,400 at a price of $46.28 per share, increasing his direct holdings to 592,724 shares.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> ARE Executive Chairman Joel S. Marcus acquired 5,000 shares of common stock through an open market purchase on August 17, 2026. The transaction totaled $231,400 at a price of $46.28 per share, increasing his direct holdings to 592,724 shares.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> VRSN Executive Chairman, President, & CEO D. James Bidzos Sold $916,909 Shares on August 18 https://www.nycmemo.com/news/VRSN-Executive-Chairman-President-CEO-D-James-Bidzos-Sold-916909-Shares-on?utm_source=newstex&utm_medium=rss nycmemo:wire:ab11bb4e-8e49-4e1e-abdc-2a7fa5da00ee Wed, 19 Aug 2026 20:35:31 GMT The NYC Memo insider sale VRSN VRSN's Executive Chairman, President, and CEO D. James Bidzos disposed of 3,300 shares of common stock on August 18, 2026. The total transaction value for these sales amounted to $916,909.94. Following these transactions, Mr. Bidzos directly held 401,388.66 shares of VRSN.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> VRSN's Executive Chairman, President, and CEO D. James Bidzos disposed of 3,300 shares of common stock on August 18, 2026. The total transaction value for these sales amounted to $916,909.94. Following these transactions, Mr. Bidzos directly held 401,388.66 shares of VRSN.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> NDSN Reports Q3 2026 Record Sales $818M (+10%), GAAP EPS $2.73 (+23%), Raises FY Guidance https://www.nycmemo.com/news/NDSN-Reports-Q3-2026-Record-Sales-818M-10-GAAP-EPS-273-23-Raises-FY-Guidance?utm_source=newstex&utm_medium=rss nycmemo:wire:3e5af2e7-4a15-4839-b489-d0213148b27c Wed, 19 Aug 2026 20:32:10 GMT The NYC Memo earnings announcement NDSN Nordson Corporation announced record sales of $818 million, an increase of 10% year-over-year, and GAAP earnings per diluted share of $2.73, up 23% year-over-year, for its third quarter fiscal 2026 results on August 19, 2026. Adjusted earnings per diluted share were $3.25, a 19% increase from the prior year. The company also updated its full-year guidance, raising sales to $3,035 million-$3,075 million and adjusted EPS to $11.80-$12.00.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Nordson Corporation announced record sales of $818 million, an increase of 10% year-over-year, and GAAP earnings per diluted share of $2.73, up 23% year-over-year, for its third quarter fiscal 2026 results on August 19, 2026. Adjusted earnings per diluted share were $3.25, a 19% increase from the prior year. The company also updated its full-year guidance, raising sales to $3,035 million-$3,075 million and adjusted EPS to $11.80-$12.00.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> CPRT Details President Jane Pocock's $804K Base Salary, $800K RSU Grant, 500K Stock Options https://www.nycmemo.com/news/CPRT-Details-President-Jane-Pococks-804K-Base-Salary-800K-RSU-Grant-500K-Stock?utm_source=newstex&utm_medium=rss nycmemo:wire:aeeb8628-edee-4660-91a9-9e1f079ee631 Wed, 19 Aug 2026 20:27:01 GMT The NYC Memo executive change CPRT Copart, Inc.'s Compensation Committee approved compensation for President Jane Pocock, effective August 1, 2026, which includes an annual base salary of $804,000 and a target annual bonus of $643,000. She also received an $800,000 restricted stock unit grant, vesting over five years, and a stock option to purchase 500,000 shares, also vesting over five years, with 279,000 options performance-based.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Copart, Inc.'s Compensation Committee approved compensation for President Jane Pocock, effective August 1, 2026, which includes an annual base salary of $804,000 and a target annual bonus of $643,000. She also received an $800,000 restricted stock unit grant, vesting over five years, and a stock option to purchase 500,000 shares, also vesting over five years, with 279,000 options performance-based.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> TDG Director Howley W Nicholas Sold $13.2M Shares on August 18, 2026 https://www.nycmemo.com/news/TDG-Director-Howley-W-Nicholas-Sold-132M-Shares-on-August-18-2026?utm_source=newstex&utm_medium=rss nycmemo:wire:2ab3ed68-8c5a-43af-b93f-52996482168f Wed, 19 Aug 2026 20:21:10 GMT The NYC Memo insider sale TDG TransDigm Group Incorporated Director Howley W Nicholas disposed of 10,132 shares of common stock on August 18, 2026, across multiple transactions. The sales totaled approximately $13.2 million, at prices ranging from $1,225.60 to $1,241.14 per share. Following these transactions, Howley W Nicholas beneficially owned 21,547.513 shares.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> TransDigm Group Incorporated Director Howley W Nicholas disposed of 10,132 shares of common stock on August 18, 2026, across multiple transactions. The sales totaled approximately $13.2 million, at prices ranging from $1,225.60 to $1,241.14 per share. Following these transactions, Howley W Nicholas beneficially owned 21,547.513 shares.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> RJF Discloses July 2026 Operating Data: Client Assets Grew to $1.93 Trillion https://www.nycmemo.com/news/RJF-Discloses-July-2026-Operating-Data?utm_source=newstex&utm_medium=rss nycmemo:wire:1e3cd44c-3dac-4a23-a5db-0f7ed82ce6ba Wed, 19 Aug 2026 20:18:36 GMT The NYC Memo financial results RJF Raymond James Financial, Inc. (RJF) reported its July 2026 operating data, including record client assets under administration of $1.93 trillion, a 17% increase year-over-year. Private Client Group assets in fee-based accounts rose 21% year-over-year to $1.16 trillion, while financial assets under management totaled $344.6 billion. Bank loans, net, were $56.3 billion, up 13% year-over-year, and clients' domestic cash sweep and Enhanced Savings Program balances were $56.7 billion.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Raymond James Financial, Inc. (RJF) reported its July 2026 operating data, including record client assets under administration of $1.93 trillion, a 17% increase year-over-year. Private Client Group assets in fee-based accounts rose 21% year-over-year to $1.16 trillion, while financial assets under management totaled $344.6 billion. Bank loans, net, were $56.3 billion, up 13% year-over-year, and clients' domestic cash sweep and Enhanced Savings Program balances were $56.7 billion.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> AMD Director Joe Householder Retired; Tim Ryan Appointed Independent Director, Effective August 19 https://www.nycmemo.com/news/AMD-Director-Joe-Householder-Retired-Tim-Ryan-Appointed-Independent-Director?utm_source=newstex&utm_medium=rss nycmemo:wire:98310258-15b7-4f86-93d2-e52f974a6c0d Wed, 19 Aug 2026 20:16:56 GMT The NYC Memo executive change AMD Advanced Micro Devices, Inc. announced Joe Householder's retirement from its Board of Directors, effective August 19, 2026, after serving since 2014. Following this, Tim Ryan was appointed as an independent director, effective August 19, 2026. KC McClure succeeded Mr. Householder as Chair of the Audit and Finance Committee and joined the Nominating and Corporate Governance Committee, while Nora Denzel joined the Audit and Finance Committee.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Advanced Micro Devices, Inc. announced Joe Householder's retirement from its Board of Directors, effective August 19, 2026, after serving since 2014. Following this, Tim Ryan was appointed as an independent director, effective August 19, 2026. KC McClure succeeded Mr. Householder as Chair of the Audit and Finance Committee and joined the Nominating and Corporate Governance Committee, while Nora Denzel joined the Audit and Finance Committee.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> BG Subsidiary Issues $600M of 5.000% Senior Notes Due 2031, Netting $593.8M https://www.nycmemo.com/news/BG-Subsidiary-Issues-600M-of-5000-Senior-Notes-Due-2031-Netting-5938M?utm_source=newstex&utm_medium=rss nycmemo:wire:8dfe4e32-867e-4957-9798-d47f95517679 Wed, 19 Aug 2026 20:15:35 GMT The NYC Memo material agreement BG Bunge Limited Finance Corp., a subsidiary of Bunge Global SA, completed the sale and issuance of $600 million aggregate principal amount of 5.000% Senior Notes due 2031 on August 19, 2026. The notes, guaranteed by Bunge, resulted in net proceeds of approximately $593.8 million, intended for general corporate purposes including debt repayment and refinancing.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Bunge Limited Finance Corp., a subsidiary of Bunge Global SA, completed the sale and issuance of $600 million aggregate principal amount of 5.000% Senior Notes due 2031 on August 19, 2026. The notes, guaranteed by Bunge, resulted in net proceeds of approximately $593.8 million, intended for general corporate purposes including debt repayment and refinancing.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> HAS: President John Hight Sold 11,593 Shares for $1.10 Million on August 19 https://www.nycmemo.com/news/HAS-3?utm_source=newstex&utm_medium=rss nycmemo:wire:7efe91e7-5ae0-4ef9-9041-332032389e62 Wed, 19 Aug 2026 20:13:33 GMT The NYC Memo insider sale HAS Hasbro Inc. (HAS) President of Wizards of the Coast, John Hight, sold 11,593 shares of common stock on August 19, 2026. The shares were disposed of at a price of $94.63 per share, totaling $1,097,045.59. Following the transaction, Mr. Hight directly owns 38,597 shares.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Hasbro Inc. (HAS) President of Wizards of the Coast, John Hight, sold 11,593 shares of common stock on August 19, 2026. The shares were disposed of at a price of $94.63 per share, totaling $1,097,045.59. Following the transaction, Mr. Hight directly owns 38,597 shares.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> MPC Chief Legal Officer Molly R. Benson Sold $6.16M Shares on August 17, 2026 https://www.nycmemo.com/news/MPC-Chief-Legal-Officer-Molly-R-Benson-Sold-616M-Shares-on-August-17-2026?utm_source=newstex&utm_medium=rss nycmemo:wire:70abec2a-2491-4cf5-b47f-98364f3b274d Wed, 19 Aug 2026 20:08:16 GMT The NYC Memo insider sale MPC Molly R. Benson, Marathon Petroleum Corporation's Chief Legal Officer and Corporate Secretary, disposed of 17,196 shares on August 17, 2026, following the exercise of stock options. The total value of the shares sold was approximately $6,165,969.72 at an average price of $358.57 per share.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Molly R. Benson, Marathon Petroleum Corporation's Chief Legal Officer and Corporate Secretary, disposed of 17,196 shares on August 17, 2026, following the exercise of stock options. The total value of the shares sold was approximately $6,165,969.72 at an average price of $358.57 per share.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> WFC Designates, Sells 1.75M Depositary Shares of 6.55% Series HH Preferred Stock https://www.nycmemo.com/news/WFC-Designates-Sells-175M-Depositary-Shares-of-655-Series-HH-Preferred-Stock?utm_source=newstex&utm_medium=rss nycmemo:wire:6d0df9f9-f0f8-49f1-89ba-7dfcd7ba7fc7 Wed, 19 Aug 2026 20:08:07 GMT The NYC Memo material agreement WFC Wells Fargo & Company on August 17, 2026, designated 70,000 shares of "6.55% Fixed Rate Reset Non-Cumulative Perpetual Class A Preferred Stock, Series HH" with a $25,000 per share liquidation preference. On August 19, 2026, the company sold 1,750,000 Depositary Shares, each representing a 1/25th interest in the new Series HH Preferred Stock.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Wells Fargo & Company on August 17, 2026, designated 70,000 shares of "6.55% Fixed Rate Reset Non-Cumulative Perpetual Class A Preferred Stock, Series HH" with a $25,000 per share liquidation preference. On August 19, 2026, the company sold 1,750,000 Depositary Shares, each representing a 1/25th interest in the new Series HH Preferred Stock.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Prince Bakery Inc Issues Allergy Alert on Undeclared Milk and Sesame in Prince Bakery Breads https://www.nycmemo.com/news/Prince-Bakery-Inc-Issues-Allergy-Alert-on-Undeclared-Milk-and-Sesame-in-Prince?utm_source=newstex&utm_medium=rss nycmemo:wire:a218ce39-84a4-4041-a778-7db5f01d5e0f Wed, 19 Aug 2026 19:57:00 GMT The NYC Memo Markets Prince Bakery Inc issued a voluntary allergy alert for its bread products due to undeclared milk and sesame, both major allergens under FDA labeling requirements. The recall affects consumers with dairy or sesame sensitivities and triggers standard FDA Class II or III recall protocols pending severity assessment. No publicly traded tickers are directly implicated; this is a private-label bakery recall with negligible broad market impact.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Prince Bakery Inc issued a voluntary allergy alert for its bread products due to undeclared milk and sesame, both major allergens under FDA labeling requirements. The recall affects consumers with dairy or sesame sensitivities and triggers standard FDA Class II or III recall protocols pending severity assessment. No publicly traded tickers are directly implicated; this is a private-label bakery recall with negligible broad market impact.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> HAL Director, EVP, and COO Slocum Sold 16,121 Shares for $565,573 https://www.nycmemo.com/news/HAL-Director-EVP-and-COO-Slocum-Sold-16121-Shares-for-565573?utm_source=newstex&utm_medium=rss nycmemo:wire:f4810031-104a-4584-ba00-b19a1c3cffd4 Wed, 19 Aug 2026 19:21:08 GMT The NYC Memo insider sale HAL Halliburton Director, EVP, and COO Jeffrey Shannon Slocum disposed of 16,121 shares of common stock on August 18, 2026. The shares were sold at a price of $35.083 per share, totaling $565,573.043.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Halliburton Director, EVP, and COO Jeffrey Shannon Slocum disposed of 16,121 shares of common stock on August 18, 2026. The shares were sold at a price of $35.083 per share, totaling $565,573.043.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> HAL CEO Jeffrey Miller Sold 124,483 Shares for $4.36M on August 18 https://www.nycmemo.com/news/HAL-CEO-Jeffrey-Miller-Sold-124483-Shares-for-436M-on-August-18?utm_source=newstex&utm_medium=rss nycmemo:wire:fde2fbe1-8257-4cfa-8083-82bc3a8d6644 Wed, 19 Aug 2026 19:20:52 GMT The NYC Memo insider sale HAL Halliburton (HAL) Director, President, and CEO Jeffrey Allen Miller disposed of 124,483 common shares on August 18, 2026. The shares were sold at a price of $35.00 per share, totaling $4,356,905 in value. This transaction was not executed under a 10b5-1 trading plan.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Halliburton (HAL) Director, President, and CEO Jeffrey Allen Miller disposed of 124,483 common shares on August 18, 2026. The shares were sold at a price of $35.00 per share, totaling $4,356,905 in value. This transaction was not executed under a 10b5-1 trading plan.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Truth Social: No one has given the Islamic Republic of Iran a greater opportunity to make a Deal than me. https://www.nycmemo.com/news/Truth-Social-382?utm_source=newstex&utm_medium=rss nycmemo:wire:9e39d204-2581-4bfd-97c0-bce37839cdb2 Wed, 19 Aug 2026 18:59:00 GMT The NYC Memo presidential statement XOM CVX COP OXY HAL SLB The President announced sweeping, unprecedented economic sanctions and financial isolation against Iran, with secondary sanctions threatened against any country or entity providing economic lifelines to Iran, likely driving oil prices higher, boosting defense and tanker equities, pressuring financials with EM exposure, and strengthening the USD against regional and sanction-risk currencies.

Primary source: Truth Social. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The President announced sweeping, unprecedented economic sanctions and financial isolation against Iran, with secondary sanctions threatened against any country or entity providing economic lifelines to Iran, likely driving oil prices higher, boosting defense and tanker equities, pressuring financials with EM exposure, and strengthening the USD against regional and sanction-risk currencies.

Primary source: Truth Social. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> NUE Chair and CEO Leon Topalian Sold $8.09M Shares on August 14, 2026 https://www.nycmemo.com/news/NUE-Chair-and-CEO-Leon-Topalian-Sold-809M-Shares-on-August-14-2026?utm_source=newstex&utm_medium=rss nycmemo:wire:b940eb67-02d4-4b86-b05b-4cd653d5586b Wed, 19 Aug 2026 18:42:01 GMT The NYC Memo insider sale NUE Nucor Corporation Chair and CEO Leon J Topalian disposed of 26,000 shares of NUE common stock on August 14, 2026, for a total value of approximately $8.09 million. The transactions included sales at average prices of $268.518 and $269.29 per share, following the exercise of 26,000 options at $42.46 per share. Following these transactions, Topalian directly owned 138,154.47 shares.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Nucor Corporation Chair and CEO Leon J Topalian disposed of 26,000 shares of NUE common stock on August 14, 2026, for a total value of approximately $8.09 million. The transactions included sales at average prices of $268.518 and $269.29 per share, following the exercise of 26,000 options at $42.46 per share. Following these transactions, Topalian directly owned 138,154.47 shares.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Minutes of the Federal Open Market Committee, July 28–29, 2026 https://www.nycmemo.com/news/Minutes-of-the-Federal-Open-Market-Committee-July-2829-2026?utm_source=newstex&utm_medium=rss nycmemo:wire:9456f691-7cd1-469f-9d18-9d07a3e3f8ed Wed, 19 Aug 2026 18:00:00 GMT The NYC Memo Markets The Federal Reserve published minutes from the July 28-29, 2026 FOMC meeting, providing granular detail on policymakers' debate over the pace and trajectory of monetary policy. The minutes reveal the internal consensus or dissent behind the committee's rate decision, including member assessments of inflation progress, labor market conditions, and forward guidance language. Traders will parse the minutes for hawkish or dovish shifts in vote distribution and any updated signals on the timing of future rate moves, with particular attention to implications for rate-sensitive sectors including financials (XLF), REITs (VNQ), and Treasuries (TLT).

Primary source: Federal Reserve FOMC. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The Federal Reserve published minutes from the July 28-29, 2026 FOMC meeting, providing granular detail on policymakers' debate over the pace and trajectory of monetary policy. The minutes reveal the internal consensus or dissent behind the committee's rate decision, including member assessments of inflation progress, labor market conditions, and forward guidance language. Traders will parse the minutes for hawkish or dovish shifts in vote distribution and any updated signals on the timing of future rate moves, with particular attention to implications for rate-sensitive sectors including financials (XLF), REITs (VNQ), and Treasuries (TLT).

Primary source: Federal Reserve FOMC. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device https://www.nycmemo.com/news/FDA-Authorizes-First-Of-Its-Kind-Robotic-Blood-Draw-Device?utm_source=newstex&utm_medium=rss nycmemo:wire:15e351ae-581d-4613-8761-3246cc254587 Wed, 19 Aug 2026 16:48:13 GMT The NYC Memo Markets The FDA has authorized the first robotic blood-draw device, marking a regulatory first for autonomous venipuncture technology in clinical settings. The cleared device bypasses the need for trained phlebotomists, with implications for diagnostic lab throughput, point-of-care efficiency, and hospital staffing economics. No ticker is formally attached to this release; traders should monitor Drawbridge Health and Vitestro (both private) alongside publicly traded lab services plays LH and DGX, which face potential long-term workflow disruption.

Primary source: FDA. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA has authorized the first robotic blood-draw device, marking a regulatory first for autonomous venipuncture technology in clinical settings. The cleared device bypasses the need for trained phlebotomists, with implications for diagnostic lab throughput, point-of-care efficiency, and hospital staffing economics. No ticker is formally attached to this release; traders should monitor Drawbridge Health and Vitestro (both private) alongside publicly traded lab services plays LH and DGX, which face potential long-term workflow disruption.

Primary source: FDA. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> EL Discloses Ongoing Securities, Talcum Litigation; Restructuring Program Extends to Q1 2026 https://www.nycmemo.com/news/EL-Discloses-Ongoing-Securities-Talcum-Litigation-Restructuring-Program-Extends?utm_source=newstex&utm_medium=rss nycmemo:wire:efdeaa49-86d6-4118-ba30-3f6ddc612bc7 Wed, 19 Aug 2026 16:29:06 GMT The NYC Memo restructuring EL Estée Lauder Companies Inc. (EL) disclosed ongoing litigation risks, specifically a 'Securities Class Action' and 'Talcum Litigation,' with associated expenses recorded for fiscal years 2026, 2025, and 2024. The company's Restructuring Program, initiated in February 2024, is ongoing with activity expected through Q1 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Estée Lauder Companies Inc. (EL) disclosed ongoing litigation risks, specifically a 'Securities Class Action' and 'Talcum Litigation,' with associated expenses recorded for fiscal years 2026, 2025, and 2024. The company's Restructuring Program, initiated in February 2024, is ongoing with activity expected through Q1 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Optimal Balance Pharmacy Recalls Compounded Glutathione 200 mg/mL Vials Nationwide Over Elevated Endotoxin Levels https://www.nycmemo.com/news/Optimal-Balance-Pharmacy-Issues-Voluntary-Nationwide-Recall-of-Certain-Lots-of?utm_source=newstex&utm_medium=rss nycmemo:wire:d7add45f-ce40-4d2b-bcdb-146aa528830f Wed, 19 Aug 2026 14:00:00 GMT The NYC Memo fda recall Optimal Balance Pharmacy issued a voluntary nationwide recall of select lots of compounded glutathione 200 mg/mL multi-dose vials after testing revealed elevated endotoxin levels, which pose risk of fever, sepsis, or death upon injection. The recall covers a compounded product with no branded equivalent, limiting direct public market exposure. No publicly traded sponsor ticker is implicated; compounding pharmacy sector participants and IV-therapy adjacent plays warrant monitoring for regulatory scrutiny spillover.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Optimal Balance Pharmacy issued a voluntary nationwide recall of select lots of compounded glutathione 200 mg/mL multi-dose vials after testing revealed elevated endotoxin levels, which pose risk of fever, sepsis, or death upon injection. The recall covers a compounded product with no branded equivalent, limiting direct public market exposure. No publicly traded sponsor ticker is implicated; compounding pharmacy sector participants and IV-therapy adjacent plays warrant monitoring for regulatory scrutiny spillover.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device - fda.gov https://www.nycmemo.com/news/FDA-Authorizes-First-Of-Its-Kind-Robotic-Blood-Draw-Device-fdagov?utm_source=newstex&utm_medium=rss nycmemo:wire:9f898a52-6e61-4f98-b792-90236aae6f36 Wed, 19 Aug 2026 14:00:00 GMT The NYC Memo Markets The FDA has authorized the first-of-its-kind robotic venipuncture device, marking a regulatory first for fully automated blood collection technology. The cleared device targets high-volume clinical and hospital settings, reducing reliance on skilled phlebotomy staff. Privately held Vitestro is the primary developer in this space; watch diagnostics incumbents Quest Diagnostics (DGX) and Laboratory Corporation (LH) for workflow disruption risk, alongside medical robotics plays ISRG and XRAY.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA has authorized the first-of-its-kind robotic venipuncture device, marking a regulatory first for fully automated blood collection technology. The cleared device targets high-volume clinical and hospital settings, reducing reliance on skilled phlebotomy staff. Privately held Vitestro is the primary developer in this space; watch diagnostics incumbents Quest Diagnostics (DGX) and Laboratory Corporation (LH) for workflow disruption risk, alongside medical robotics plays ISRG and XRAY.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> TJX Reports Q2 FY27 Net Sales of $15.2B (+5%), Diluted EPS $1.36 (+24%) https://www.nycmemo.com/news/TJX-Reports-Q2-FY27-Net-Sales-of-152B-5-Diluted-EPS-136-24?utm_source=newstex&utm_medium=rss nycmemo:wire:9d81faa7-11a6-414d-a1be-d5cd1a67c4e0 Wed, 19 Aug 2026 13:09:11 GMT The NYC Memo earnings announcement TJX The TJX Companies, Inc. announced Q2 FY27 financial results on August 19, 2026, reporting net sales of $15.2 billion, a 5% year-over-year increase. Diluted earnings per share reached $1.36, up 24% from $1.10 in Q2 FY26, with adjusted diluted EPS at $1.22, an 11% increase. Consolidated comparable sales grew by 4% for the quarter ended August 1, 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The TJX Companies, Inc. announced Q2 FY27 financial results on August 19, 2026, reporting net sales of $15.2 billion, a 5% year-over-year increase. Diluted earnings per share reached $1.36, up 24% from $1.10 in Q2 FY26, with adjusted diluted EPS at $1.22, an 11% increase. Consolidated comparable sales grew by 4% for the quarter ended August 1, 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> PGR Reports July 2026 Net Premiums Earned $7.355B, Diluted EPS $1.65 https://www.nycmemo.com/news/PGR-Reports-July-2026-Net-Premiums-Earned-7355B-Diluted-EPS-165?utm_source=newstex&utm_medium=rss nycmemo:wire:3f0c50a9-0598-4b93-89b7-912b224138d9 Wed, 19 Aug 2026 13:08:04 GMT The NYC Memo financial results PGR The Progressive Corporation disclosed July 2026 financial results via an August 19, 2026 news release. For July, net premiums earned were $7.355 billion and diluted EPS was $1.65, representing a 5% increase and an 11% decrease year-over-year, respectively. The combined ratio for July 2026 was 86.8, with year-to-date 2026 net premiums earned reaching $49.896 billion and diluted EPS at $12.12.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The Progressive Corporation disclosed July 2026 financial results via an August 19, 2026 news release. For July, net premiums earned were $7.355 billion and diluted EPS was $1.65, representing a 5% increase and an 11% decrease year-over-year, respectively. The combined ratio for July 2026 was 86.8, with year-to-date 2026 net premiums earned reaching $49.896 billion and diluted EPS at $12.12.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> LOW Reports Q2 2026 Net Earnings $2.4B, Diluted EPS $4.27, Sales $26.0B; Updates FY26 Outlook https://www.nycmemo.com/news/LOW-Reports-Q2-2026-Net-Earnings-24B-Diluted-EPS-427-Sales-260B-Updates-FY26?utm_source=newstex&utm_medium=rss nycmemo:wire:f8837dec-9125-4950-90b8-7e182f1326ed Wed, 19 Aug 2026 12:45:07 GMT The NYC Memo earnings announcement LOW Lowe's Companies, Inc. reported second quarter 2026 financial results, including net earnings of $2.4 billion, diluted EPS of $4.27, and adjusted diluted EPS of $4.40 for the period ended July 31, 2026. Total sales for the quarter reached $26.0 billion, with comparable sales increasing 0.2% year-over-year. The company also updated its full-year 2026 outlook, expecting total sales of $92.0 billion and diluted EPS of approximately $11.75.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Lowe's Companies, Inc. reported second quarter 2026 financial results, including net earnings of $2.4 billion, diluted EPS of $4.27, and adjusted diluted EPS of $4.40 for the period ended July 31, 2026. Total sales for the quarter reached $26.0 billion, with comparable sales increasing 0.2% year-over-year. The company also updated its full-year 2026 outlook, expecting total sales of $92.0 billion and diluted EPS of approximately $11.75.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> MRVL: Marvell to Develop Custom Semiconductors for Google; Issues 58.97M Share Warrant at $206.58 https://www.nycmemo.com/news/MRVL?utm_source=newstex&utm_medium=rss nycmemo:wire:54d5073c-b062-4ae2-b36a-8e94e0e68291 Wed, 19 Aug 2026 12:25:06 GMT The NYC Memo material agreement MRVL Marvell Technology, Inc. and Google LLC entered a commercial agreement on July 29, 2026, for Marvell to develop custom semiconductor products, including AI accelerators. In connection, Marvell issued Google a warrant on August 18, 2026, to purchase up to 58,970,907 shares at $206.58 per share. A portion of shares will vest quarterly over one year, with remaining shares vesting in tranches tied to each $500 million in custom products revenue from Q3 fiscal year 2027 through fiscal year 2033.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Marvell Technology, Inc. and Google LLC entered a commercial agreement on July 29, 2026, for Marvell to develop custom semiconductor products, including AI accelerators. In connection, Marvell issued Google a warrant on August 18, 2026, to purchase up to 58,970,907 shares at $206.58 per share. A portion of shares will vest quarterly over one year, with remaining shares vesting in tranches tied to each $500 million in custom products revenue from Q3 fiscal year 2027 through fiscal year 2033.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> HON Appoints Hammoud as Process Tech CEO, Picon as Building Automation CEO; West Departs https://www.nycmemo.com/news/HON-Appoints-Hammoud-as-Process-Tech-CEO-Picon-as-Building-Automation-CEO-West?utm_source=newstex&utm_medium=rss nycmemo:wire:4f5adda8-a072-41a2-a512-e487be6c8590 Wed, 19 Aug 2026 12:16:48 GMT The NYC Memo executive change HON Honeywell International Inc. appointed Billal Hammoud as President and CEO of Process Technology and Juan Picon as President and CEO of Building Automation, both effective October 1, 2026. Mr. Hammoud was previously CEO of Building Automation, while Mr. Picon was President of Building Automation Americas. Ken West, the current President and CEO of Process Technology, will depart the company on August 31, 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Honeywell International Inc. appointed Billal Hammoud as President and CEO of Process Technology and Juan Picon as President and CEO of Building Automation, both effective October 1, 2026. Mr. Hammoud was previously CEO of Building Automation, while Mr. Picon was President of Building Automation Americas. Ken West, the current President and CEO of Process Technology, will depart the company on August 31, 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> BAX Appoints John Rogers CFO, $925K Salary, $4M Equity; Andrew Hider Interim CFO https://www.nycmemo.com/news/BAX-Appoints-John-Rogers-CFO-925K-Salary-4M-Equity-Andrew-Hider-Interim-CFO?utm_source=newstex&utm_medium=rss nycmemo:wire:c59cd7f5-1b3b-450a-8d74-be71ab49873f Wed, 19 Aug 2026 12:07:42 GMT The NYC Memo executive change BAX Baxter International Inc. appointed John Rogers Executive Vice President and Chief Financial Officer, effective October 1, 2026. Rogers will receive an annual base salary of $925,000, a target annual bonus of 100% of salary, a target annual equity grant value of $4,000,000, and a sign-on bonus of $2,827,629. Additionally, Andrew Hider was appointed interim CFO from September 15, 2026, until October 1, 2026, and Bernie Heine became interim Chief Accounting Officer, effective September 15, 2026, receiving an additional $15,000 monthly and a $250,000 restricted stock unit award.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Baxter International Inc. appointed John Rogers Executive Vice President and Chief Financial Officer, effective October 1, 2026. Rogers will receive an annual base salary of $925,000, a target annual bonus of 100% of salary, a target annual equity grant value of $4,000,000, and a sign-on bonus of $2,827,629. Additionally, Andrew Hider was appointed interim CFO from September 15, 2026, until October 1, 2026, and Bernie Heine became interim Chief Accounting Officer, effective September 15, 2026, receiving an additional $15,000 monthly and a $250,000 restricted stock unit award.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> TGT Reports Q2 2026 GAAP, Adjusted EPS of $4.11, Up 100%, Net Sales $26.5B, Up 5.3% https://www.nycmemo.com/news/TGT-Reports-Q2-2026-GAAP-Adjusted-EPS-of-411-Up-100-Net-Sales-265B-Up-53?utm_source=newstex&utm_medium=rss nycmemo:wire:2fa9b299-79bb-458f-868e-702b70f91ee1 Wed, 19 Aug 2026 11:51:13 GMT The NYC Memo earnings announcement TGT Target Corporation announced Q2 2026 financial results on August 19, 2026, reporting GAAP and Adjusted EPS of $4.11, a 100% increase from the prior year, benefiting from $1.65 per share in tariff refunds. Net sales grew 5.3% to $26.5 billion, with comparable sales up 3.8% driven by a 3.6% increase in comparable traffic. Operating income was $2.6 billion, representing a 9.6% margin rate, which included 3.7 percentage points of benefit from tariff refunds.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Target Corporation announced Q2 2026 financial results on August 19, 2026, reporting GAAP and Adjusted EPS of $4.11, a 100% increase from the prior year, benefiting from $1.65 per share in tariff refunds. Net sales grew 5.3% to $26.5 billion, with comparable sales up 3.8% driven by a 3.6% increase in comparable traffic. Operating income was $2.6 billion, representing a 9.6% margin rate, which included 3.7 percentage points of benefit from tariff refunds.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> ADI Reports Q3 2026 Revenue $4.02B, EPS $2.74, Discloses $267M IRS Transfer Pricing Assessment https://www.nycmemo.com/news/ADI-Reports-Q3-2026-Revenue-402B-EPS-274-Discloses-267M-IRS-Transfer-Pricing?utm_source=newstex&utm_medium=rss nycmemo:wire:04ddff70-8007-490f-94f0-07b9378daedc Wed, 19 Aug 2026 11:04:23 GMT The NYC Memo financial results ADI Analog Devices (ADI) reported Q3 2026 revenue of $4.02 billion, a 40% year-over-year increase, with diluted EPS rising 163% year-over-year to $2.74. The company also disclosed receiving a $267.0 million assessment from the U.S. IRS for fiscal 2018 and 2019 related to transfer pricing, which it intends to defend.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Analog Devices (ADI) reported Q3 2026 revenue of $4.02 billion, a 40% year-over-year increase, with diluted EPS rising 163% year-over-year to $2.74. The company also disclosed receiving a $267.0 million assessment from the U.S. IRS for fiscal 2018 and 2019 related to transfer pricing, which it intends to defend.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> ADI Reports Q3 Fiscal 2026 Revenue $4.02B, GAAP EPS $2.74, Adjusted EPS $3.45 https://www.nycmemo.com/news/ADI-Reports-Q3-Fiscal-2026-Revenue-402B-GAAP-EPS-274-Adjusted-EPS-345?utm_source=newstex&utm_medium=rss nycmemo:wire:bbdb1f49-c97a-47e4-b3ca-c80e18559f1c Wed, 19 Aug 2026 11:03:13 GMT The NYC Memo earnings announcement ADI Analog Devices, Inc. announced financial results for its fiscal third quarter ended August 1, 2026, reporting revenue of $4.02 billion, a 40% year-over-year increase. GAAP diluted earnings per share were $2.74, up 163% year-over-year, and adjusted diluted earnings per share reached $3.45, a 68% year-over-year increase. The company also reported an adjusted operating margin of 50.0% for the quarter.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Analog Devices, Inc. announced financial results for its fiscal third quarter ended August 1, 2026, reporting revenue of $4.02 billion, a 40% year-over-year increase. GAAP diluted earnings per share were $2.74, up 163% year-over-year, and adjusted diluted earnings per share reached $3.45, a 68% year-over-year increase. The company also reported an adjusted operating margin of 50.0% for the quarter.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> AVY Board Elects William Wagner Independent Chair, Effective September 1, 2026 https://www.nycmemo.com/news/AVY-Board-Elects-William-Wagner-Independent-Chair-Effective-September-1-2026?utm_source=newstex&utm_medium=rss nycmemo:wire:eb6bb223-14fd-4886-ad49-6b5ef36a1efd Wed, 19 Aug 2026 10:45:55 GMT The NYC Memo executive change AVY Avery Dennison Corporation's Board of Directors elected William Wagner as independent Board Chair on August 18, 2026, effective September 1, 2026, for a term ending at the 2027 Annual Meeting. Mitchell Butier will continue as non-executive Chairman until August 31, 2026. Patrick Siewert will cease serving as Lead Independent Director on August 31, 2026, and was appointed Chair of the Governance Committee, effective September 1, 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Avery Dennison Corporation's Board of Directors elected William Wagner as independent Board Chair on August 18, 2026, effective September 1, 2026, for a term ending at the 2027 Annual Meeting. Mitchell Butier will continue as non-executive Chairman until August 31, 2026. Patrick Siewert will cease serving as Lead Independent Director on August 31, 2026, and was appointed Chair of the Governance Committee, effective September 1, 2026.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Truth Social: The most gratifying loss last night was that of a real treasonous creep, Alexander Vindman, to a Radical Left Lunatic, who can’t speak or think properly, and who will go down to... https://www.nycmemo.com/news/Truth-Social-378?utm_source=newstex&utm_medium=rss nycmemo:wire:d3c46e89-2a8c-4486-90e5-84df1dd608ca Wed, 19 Aug 2026 10:31:00 GMT The NYC Memo presidential statement The post comments on a political primary election result and a historical impeachment proceeding, containing no policy, regulatory, trade, or fiscal content with identifiable market implications.

Primary source: Truth Social. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The post comments on a political primary election result and a historical impeachment proceeding, containing no policy, regulatory, trade, or fiscal content with identifiable market implications.

Primary source: Truth Social. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Potency Assessment of Active Immunotherapy Products - fda.gov https://www.nycmemo.com/news/Potency-Assessment-of-Active-Immunotherapy-Products-fdagov?utm_source=newstex&utm_medium=rss nycmemo:wire:73a081d2-5888-4ea9-9dcf-54336f769169 Wed, 19 Aug 2026 08:45:00 GMT The NYC Memo Markets The FDA published a guidance document outlining potency assessment frameworks for active immunotherapy products, establishing standardized testing criteria manufacturers must follow for product lot release and stability. The guidance applies broadly to developers of therapeutic cancer vaccines and other active immunotherapy modalities. No single company or ticker is directly implicated; firms with active immunotherapy pipelines including NVAX, IOVA, and NKTR face updated compliance benchmarks.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA published a guidance document outlining potency assessment frameworks for active immunotherapy products, establishing standardized testing criteria manufacturers must follow for product lot release and stability. The guidance applies broadly to developers of therapeutic cancer vaccines and other active immunotherapy modalities. No single company or ticker is directly implicated; firms with active immunotherapy pipelines including NVAX, IOVA, and NKTR face updated compliance benchmarks.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> FDA Issues Complete Response Letter Rejecting Xspray Pharma's Dasynoc NDA Application https://www.nycmemo.com/news/Xspray-Pharma-receives-Complete-Response-Letter-CRL-from-FDA-for-Dasynoc?utm_source=newstex&utm_medium=rss nycmemo:wire:a3a23d94-069f-4280-a1ba-3756e1406484 Wed, 19 Aug 2026 07:00:00 GMT The NYC Memo fda rejection XSPRAY The FDA issued a Complete Response Letter (CRL) to Xspray Pharma for Dasynoc (radotinib), a BCR-ABL tyrosine kinase inhibitor targeting chronic myeloid leukemia, blocking approval without additional data or remediation. A CRL does not constitute a final rejection but requires the sponsor to address agency deficiencies before resubmission, resetting the approval timeline by months to years. Xspray Pharma trades on Nasdaq Stockholm (XSPRAY); no U.S.-listed ticker exists, limiting direct domestic equity impact.

Primary source: Drugs.com Approvals. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA issued a Complete Response Letter (CRL) to Xspray Pharma for Dasynoc (radotinib), a BCR-ABL tyrosine kinase inhibitor targeting chronic myeloid leukemia, blocking approval without additional data or remediation. A CRL does not constitute a final rejection but requires the sponsor to address agency deficiencies before resubmission, resetting the approval timeline by months to years. Xspray Pharma trades on Nasdaq Stockholm (XSPRAY); no U.S.-listed ticker exists, limiting direct domestic equity impact.

Primary source: Drugs.com Approvals. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> Class 2 Device Recall Fort Defiance Industries, Automated Field Steam Sterilizer - accessdata.fda.gov https://www.nycmemo.com/news/Class-2-Device-Recall-Fort-Defiance-Industries-Automated-Field-Steam-Sterilizer?utm_source=newstex&utm_medium=rss nycmemo:wire:3a4f195f-af71-44f5-83c5-7efbee2c8aa5 Wed, 19 Aug 2026 06:13:13 GMT The NYC Memo Markets The FDA classified a recall of Fort Defiance Industries' Automated Field Steam Sterilizer as Class 2, indicating the device presents a remote probability of adverse health consequences. Class 2 recalls denote potential but non-life-threatening risk, typically requiring corrective action rather than full market withdrawal. Fort Defiance Industries is a private defense/medical equipment manufacturer with no publicly traded ticker, limiting direct equity market impact.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> The FDA classified a recall of Fort Defiance Industries' Automated Field Steam Sterilizer as Class 2, indicating the device presents a remote probability of adverse health consequences. Class 2 recalls denote potential but non-life-threatening risk, typically requiring corrective action rather than full market withdrawal. Fort Defiance Industries is a private defense/medical equipment manufacturer with no publicly traded ticker, limiting direct equity market impact.

Primary source: FDA Recalls. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> CPAY Group President Alan King Sold $16.9M in Company Stock on August 14-18 https://www.nycmemo.com/news/CPAY-Group-President-Alan-King-Sold-169M-in-Company-Stock-on-August-14-18?utm_source=newstex&utm_medium=rss nycmemo:wire:294df537-94ff-4092-8ec9-5b49fc37ab22 Wed, 19 Aug 2026 00:53:51 GMT The NYC Memo insider sale CPAY CPAY GroupPresident IntlVehiclePmts Alan King disposed of company shares totaling $16,940,553.69 across multiple transactions on August 14 and August 18, 2026. The sales occurred at average prices ranging from $410.0852 to $419.5763 per share.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]> CPAY GroupPresident IntlVehiclePmts Alan King disposed of company shares totaling $16,940,553.69 across multiple transactions on August 14 and August 18, 2026. The sales occurred at average prices ranging from $410.0852 to $419.5763 per share.

Primary source: The NYC Memo. Summary synthesized by The NYC Memo.

Read this brief on The NYC Memo.

Visit The NYC Memo. Home · Memos · News

]]>